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During the past two decades, peptides and proteins
have become an important class of potent therapeutic
drugs. They have gained significant importance in the
treatment of several severe diseases including autoim-
mune diseases, memory impairment, hormonal disorders,
organ transplantations and different cancers. Major advan-
tages of protein drugs are both their extremely specific
activity and their high tolerability (1). 
While recombinant DNA technology, which is provid-
ing exciting opportunities for new pharmaceutical devel-
opment and new approaches to the diagnosis, treatment
and prevention of diseases, has led to a significant increase
in the production of peptides and proteins for pharmaceu-
tical purposes, this has not been matched by the number of
peptide and protein based drugs available on the market.
The reasons for that are multiple: proteins highly suscepti-
bility to chemical and physical degradation, which is asso-
ciated with relevant difficulties in purification, storage and
delivery, multifaceted metabolic properties, variable tissue
penetration and toxicity related to the stimulation of the
immune or allergic reaction (2, 3, 4).
The structure and function of proteins is determined
by their amino acid sequence which defines the peptide
backbone, the primary structure. In spite of the enormous
number of naturally occurring proteins, a mere of 20 amino
acids construct proteins. The vast difference in the three-
dimensional structure and, therefore, also in protein func-
tion originates solely from a different amino acid sequence,
i.e. the unique structure of a protein is determined by the
chemical and physical properties of the amino acids aligned
within the protein sequence. The secondary structure des-
cribes the folding or the shape of the polypeptide chains
into regular, ordered structures like α-helices and β-sheets.
Furthermore, areas with increased flexibility – the so-called
turns or loops – are to be subsumed in this level of protein
structure. The domains of the secondary structure and all
noncovalent interactions such as hydrogen bonds and hydro-
phobic, electrostatic, or van der Waals interactions generate
the intrinsic, three-dimensional arrangement of a protein,
the tertiary structure. Some proteins consist of several
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Abstract
Recombinant DNA technology has led to a significant increase in the number of peptide and protein based pharmaceuti-
cals, giving a new approach to combat poorly controlled diseases. This particular development has been reached in the last two
decades. However, proteins are highly susceptible of physical and chemical degradation resulting in a decrease or complete loss
of biological activities. Reasons for their physical and chemical instabilities and the methods for their examination, become a
challenge for the pharmaceutical scientists for successful development of stabile protein - based pharmaceuticals.
The stability of protein - based pharmaceuticals is significant in terms of their pharmaceutical quality and biological activ-
ity. In addition, a right choice of suitable analytical methods is needed in order to detect an early formation of degradation prod-
ucts or modified forms.
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polypeptide chains. The quaternary structure characterises
the non-covalent interactions binding these chains into a
single protein molecule (5). For example, haemoglobin
consists of four polypeptide chains, which are associated
by one Fe2+ ion. The retention of the tertiary structure is
deemed the primary requirement for the biological activi-
ty of protein molecules. However, the biochemical and
structural complexity of these molecules is the reason for
proteins to react sensitive to even marginal changes in their
natural environment (6).
In the context of protein structure, the term stability
can be defined as the tendency to maintain a native (bio-
logically active) conformation.
As proteins and peptides continue to enter the phar-
maceutical market, their stability becomes a pressing issue
for the pharmaceutical scientists. Native proteins are only
marginally stable and highly susceptible to degradation,
both chemical and physical (7-9).
Chemical instability refers to the formation or destruction
of covalent bonds, within a protein molecule, i.e. some amino
acid side chains are chemically reactive, whereas others are
chemically inert. It has been demonstrated that „labile“
amino acid residues are susceptible to covalent modifications
via bond formation or cleavage through nonenzymatic reac-
tions, including hydrolysis, deamidation, oxidation, racemi-
sation, β-elimination and cystine destruction/disulfide ex-
change (10, 11). These changes alter the primary structure of
the protein, and impact higher level of its structure.
Physical instabilities include aggregation and precipi-
tation, and adsorption to surface (7- 9, 12,). Chemical insta-
bilities such as deamidation and disulphide bond cleavage,
may also lead to physical instabilities, and vice versa (6, 11).
The primary focus of this minireview is to present and
discuss the main reasons for the most common physical
and chemical instabilities and the methods for their detec-
tion. It is important to remember that every protein is unique,
both physically and chemically, and therefore exhibits uni-
que stability behaviour.
Denaturation
The loss of tertiary structure, and frequently also of
secondary structure is generally referred to as denaturation
of the protein. Perturbation of secondary or tertiary struc-
ture can lead to exposure of previously buried amino acid,
facilitating its chemical reactivity; thereby leading to loss
of its native or original characteristics. Denaturation can be
caused by destabilizing agents such as excipients (reducing
sugars, antioxidants, surfactants, metal ions), heat, hydrolysis
by strong acid or alkali, enzymatic action, exposure to urea
or other substances, or exposure to ultra violet light. Exci-
pients like reducing sugars can react with protein amino
groups to form schiff’s bases (Maillard reaction) which
can be shown by LC/MS (13). Antioxidants may contain
reducing agents that will destroy disulphide bonds. Several
surfactants like Tween 20 and Tween 80 can cause oxida-
tion of aminoacid due to residual peroxides present in
these materials, which can be detected by RP-HPLC (14).
Many chemical reactions involving polypeptides and pro-
teins are catalyzed by metal ions such as  Zn 2+, Cd 2+, Pb 2+.
At high temperature (80-100°), aspargine and glutamine
are susceptible to deamidation, Aspartate-Xaa peptide bonds
are susceptible to hydrolysis, disulphide bonds rupture,
and Xaa-Prolin peptide bonds undergo cis-trans isomeri-
sation (where Xaa is any amino acid). High temperature
can result in physical degradation due to irreversible dena-
turation. Residual moisture can be responsible for protein
instability in the solid state. pH has also strong influence on
denaturation and aggregation rate (15, 16).
The folded state of proteins is connected to conforma-
tional stability, which is expressed as the free energy
change ΔG during the unfolding/denaturation reaction under
physiological conditions (17). The higher the ΔG value, the
greater the stability of the protein. However, the reported
ΔG values for proteins of 45 +/- 15 kJ/mol indicate that
the folding state is only marginally more stable than the
denatured state (18). As a matter of fact, the conformation-
al stability of a protein in aqueous solution tallies with only
a few hydrogen bonds or ion pairs (2). Simplified, protein
denaturation can be described as:
Figure 1: Equation of the native and denatured state of a protein
The native state N exists in an equilibrium with a par-
tially unfolded state pU. This unfolding of the native pro-
tein can be reversible, e.g. an increase of the temperature
causes unfolding, which can be reversed by a subsequent
temperature decrease (7). Generally, the loss of the tertiary
structure implies an increase in the protein molecule’s
reactivity, which results in a decrease in their stability.
Hydrophobic regions, which were accumulated in the core
of the folded protein, are then exposed to surrounding sol-
vents. As a consequence, side reactions can now lead to an
irreversible, denatured state D. Alternatively, partially
unfolded proteins may encounter irreversible aggregation
(pU)n. Constantly elevated temperatures, extreme pHs, the
formation of interfaces during shaking, shearing, adsorpt-
ion to hydrophobic surfaces, high pressure, and denatu-
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rants such as urea and guanidine hydrochloride foster irre-
versible transitions (2,19-23).
Physical instability
Physical instability of proteins denotes that these
super structured molecules can undergo changes inde-
pendent of any chemical modification, i.e. includes the
reactions that do not involve the formation or cleavage of
covalent bonds.
Aggregation and precipitation
Protein aggregation is arguably the most common and
troubling manifestation of protein instability, encountered
in almost all stages of protein drug development, during
refolding, purification, sterilization, shipping and storage
processes (24).
The aggregation of protein molecules into non-native
assemblies in vivo can have profound pathological impli-
cations, as in the aggregation of β-amyloid proteins in
Alzheimer’s disease and the aggregation of prion protein
in numerous neurodegenerative diseases (24-26). The pre-
sence of aggregates in therapeutic protein pharmaceuticals
can cause adverse effects within patients, ranging from
immune response to anaphylactic shock (27, 28).
Protein aggregation is defined as the association of at
least two denatured protein molecules. With increasing
numbers of molecules the solubility of these species will
decrease, eventually resulting in the precipitation of the
protein. Aggregation can occur even under conditions
where the proteins native conformation is favored thermo-
dynamically compared to the unfolded state and at con-
centrations well below the proteins solubility limit (24, 29,
30). To effectively inhibit aggregation, both in vivo and in
vitro, a more complete understanding of the mechanisms
by which proteins aggregate is needed (31). 
Mechanisms of protein aggregation are still not fully
understood. One plausible mechanism is that aggregation
is catalyzed by the presence of a small amount of a con-
taminant. That contaminant could be a damaged form of
the protein product itself, host cell proteins, or even non-
protein materials such as silica particles (32). Damaged
forms of a protein product can arise from chemical modifi-
cation (such as oxidation or deamidation) and from con-
formationally damaged forms arising from thermal stress,
shear, or surface-induced denaturation. A second mecha-
nism begins with partial unfolding of the native protein
during storage. Protein conformation is not rigid – the
structure fluctuates around the time-averaged native struc-
ture to different extents depending on environmental con-
ditions. Some partially or fully unfolded protein molecules
are always present at equilibrium in all protein solutions, but
most such molecules simply refold to their native structure.
However, those unfolded proteins may instead aggregate
with other such molecules or may be incorporated into an
existing aggregate nucleus, eventually to form larger aggrega-
tes as described above. Factors such as elevated tempera-
ture, shaking (shear and air-liquid interface stress), surface
adsorption, and other physical or chemical stresses may
facilitate partial unfolding. A third aggregation mechanism
is reversible self-association of the native protein to form
oligomers. The tendency of different proteins to reversibly
associate is highly variable, and the strength of that asso-
ciation typically varies significantly with solvent condi-
tions such as pH and ionic strength. Such reversible oligo-
mers often eventually become irreversible (they are a first
step along a pathway to irreversible aggregation). Detection
of reversible aggregates can be especially challenging. One
of the reasons is that such aggregates can dissociate from
dilution during the measurement process (33-36).
Regardless of the mechanism of aggregation, prevent-
ing aggregation problems requires sensitive and reliable
technologies for quantitative determination of aggregate
content and aggregate characteristics (37). Size-exclusion
chromatography (SEC) has been a workhorse for detecting
and quantifying protein aggregation (2, 38-39). Native gel
electrophoresis and SDS-PAGE have also been used to
observe protein aggregation. Column-free techniques such
as analytical ultracentrifugation (AUC), field-flow frac-
tionation (FFF), and dynamic light scattering (DLS) now
find increasing application in aggregation analysis (36-37,
40). As it can be concluded, there are various techniques
for assessing protein aggregation, which will enable detec-
tion of dimmer and aggregate formation at the very begin-
ning. All that is important for pharmaceutical quality and
biological activity of protein - based drugs.
Chemical instability
Chemical instability of proteins can be potentiated or
induced by temperature, pH, light and composition of the
formulation buffer. Such chemical modifications may
result in alteration of structure, loss of function, acquired
immunogenicity and altered pharmacokinetics.
Oxidation
Methionine, cystine, tryptophan and tyrosine residues
are susceptible to oxidation. Air, residual peroxide con-
tent, or intense fluorescent light, can convert thioether to
sulfoxide, and then sulfone (41-46). The polysorbate-80
Maked. farm. bilt., 51, (1,2)  3-8 (2005)
5
Suzana Trajkovic-Jolevska, Jasmina Tonic-Ribarska, Aneta Dimitrovska
and polysorbate-20, which are usually used in the protein
formulations like surfactants, have a tendency to produce
peroxides, which in turn, can lead to oxidation of the
methionine residues. This peroxide contamination appears
to have a greater effect on protein oxidation than the pres-
ence of atmospheric oxygen in the vial headspace or the
effects of product foaming in the fill lines (14). Oxidative
modification can be variable (47). Peptide maps are con-
venient for detecting methionine oxidation, and RP-
HPLC is used to separate the oxidized forms. Oxidation
causes a protein to become more hydrophilic and oxidized
proteins elute before the native form in RP-HPLC (48).
Oxidation occurs in a number of proteins favored by
factors like temperature, pH etc. Most proteins lose biologi-
cal activity when oxidized. Thereby, formulation appro-
aches include addition of anti oxidants (sodium thiosul-
phate, catalase, or platinum) and adjustment of environmen-
tal conditions (pH or temperature) to prevent oxidation (49).
Deamidation
For many proteins deamidation is one of the most often
observed stability problems and occurs more rapidly than
any of the other degradation routes (14). Deamidation of
asparginine residues (glutamine residues to lesser extent)
to aspartate or isoaspartate via succinimide intermediates
(positive to negative charge) is a major cause of sponta-
neous degradation and loss of aminoacid sequence homo-
geneity. Deamidation can make protein prone to proteases
and denaturation. This can affect the in vivo half-life, acti-
vity, and conformation of protein, and also increase the
immunogenicity of certain protein. Deamidation often
results in the loss of biological activity (50, 51).
The deamidation process is mainly dependent on the
storage temperature, on the pH of the formulation buffer
and on the sequence and conformation. Deamidation can
be detected by isoelectric focussing and quantified by den-
sitometric scanning of the gel and by RP-HPLC (50, 52, 53).
A common means of determining deamidation is to digest
the protein with tripsin and to look for new peptide frag-
ments eluting slightly later than fragments containing
asparagine in RP-HPLC, because under acidic conditions
aspartic acid is slightly more hydrophobic than asparagi-
nes (50). At neutral pH, fragments containing asparagines
elute after the aspartic acid deamidation products because
they are less hydrophobic under these conditions (53).
Conclusions
Proteins are only marginally stable and highly suscep-
tible to physical and chemical degradation. Physical and
chemical instabilities of proteins are the major road barri-
ers, hindering rapid commercialization of potential pro-
tein drug candidates. Thereby, the successful development
of stabile protein-based pharmaceuticals is highly depend-
ent on a thorough understanding of their physico-chemical
and biological characteristics and of the mechanisms by
which proteins stabilizes. 
Due to the complexity and heterogeneity of protein
structures, multiple analytical methods for stability testing
must be employed. Stability indicating test methods must
be validated to be suitable to detect potential degradation
products or modified forms. Detection of degradation prod-
ucts or modified forms at the very beginning signalling the
stability changes important for pharmaceutical quality and
biological activity of protein - based pharmaceuticals. 
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Rezime
Nestabilnost na proteini: Teoretski aspekti, 
degradacioni produkti i metodi za nivno detektirawe 
Suzana Trajkovi}-Jolevska, Jasmina Toni}-Ribarska*, Aneta Dimitrovska
Farmacevtski fakultet, Univerzitet ,,Sv.Kiril i Metodij“, Vodwanska 17, 1000 Skopje, Makedonija
Klu~ni zborovi: proteini, fizi~ka stabilnost, hemiska stabilnost, metodi
Rekombinantnata DNK tehnologija dovede do zna~itelen porast na brojot na peptidni i proteinski farmacevtski
preparati, davaj}i nov pristap vo tretmanot na onie zaboluvawa, za koi dosega primenuvanite farmacevtski prepa-
rati ne davaat zadovolitelni rezultati. Osobeno brz razvoj na ova pole e postignat vo poslednite dve decenii.
Me|utoa, kako problem se javuva nestabilnosta na proteinskite molekuli. Imeno, poznato e deka proteinite se pod-
lo`ni na fizi~ka i hemiska degradacija, {to rezultira so namaluvawe ili celosno gubewe na nivnata biolo{ka
aktivnost. Tokmu poradi toa, pri~inite {to doveduvaat do nivna fizi~ka i hemiska nestabilnost, kako i metodite
za nivno ispituvawe, pretstavuvaat predizvik za farmacevtite za razvoj na stabilni proteinski farmacevtski
preparati.
Stabilnosta na proteinskite farmacevtski preparati e mnogu zna~ajna vo odnos na nivniot farmacevtski kva-
litet i biolo{ka aktivnost. Poradi toa, potreben e pravilen izbor na soodvetni analiti~ki metodi koi }e ovozmo-
`at detektirawe vo po~etniot stadium na formiraweto na degdradacionite produkti ili modificirani formi.
Introduction
It has been clearly demonstrated that the renal cells are
not fully differentiated at birth and that many of the differ-
ences in renal function seen between infants and adults
should be attributed to immaturity (1). This renal immaturity
does not seem to carry any risk in healthy full-term infants
fed an appropriate diet, but can represent a major risk in sit-
uation of disease, inappropriate fluid and electrolyte losses,
and exogenous pharmacologic stress (2).
Renal insufficiency and renal failure of newborns in an
intensive care unit is a very common problem. It was reported
that between 8 and 24 % of neonates in special care wards ex-
perience renal failure (3). Acute renal failure is a recognized
complication of birth asphyxia and may result in permanent
renal damage in up to 40 % of survivors (4).
Taking all these facts into account it is obvious that
evaluation of renal glomerular and tubular functional and
structural integrity in neonates is of great importance.  For
this purpose in clinical practice the investigation of a bat-
tery of biochemical parameters is frequently undertaken.
Measuring of serum concentration of creatinine, as
well as cistatin C is frequently used as a parameters for
evaluation of glomerular function (5). A more precise
assessment of the functional capacity of the kidney is
made by measuring glomerular filtration rate (GFR), but
this procedure is expensive, time consuming and invasive
because puncture of peripheral vein is necessary to obtain
several blood samples (6,7).
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Abstract
The pattern of urinary proteins in healthy full-term neonates was examined by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE), coupled with determination of few parameters related to urinary protein excretion.
Twenty healthy full-term neonates were included in the investigation. Five urine samples from each subject were collected on days 3, 7,
14, 21 and 28 after birth. Determination of total proteins was performed using turbidimetric method with sulfosalicylic acid. Urinary creati-
nine concentration was determined by Jaffe method. Urinary proteins were separated by horizontal gradient SDS-PAGE according to Görg.
The highest values for total urinary proteins and for protein/creatinine ratio were detected in urine samples excreted on days 3 and 7
after birth. Three types of SDS-PAG electrophoretic profiles were observed. The first type of electrophoretic profile was characterized by
the presence of proteins of mixed glomerular and tubular origin with molecular weights from 10 to 160 kDa. Typical for the second type
of electrophoretic profile was the presence of two faint fractions with molecular weights of 78 and 90 kDa and several intensive low
molecular weight fractions (14-67 kDa). In the third type of electrophoretic profile only low molecular weight proteins (10-67 kDa) were
detected in all five urine samples. These findings express the transitory immaturity of the glomerular filter and tubular protein reabsorbing
system of the newborn kidney. Apparently, the tubular protein handling normalizes later than the glomerular filtration of proteins.
Key words: Proteinuria; neonates; SDS-PAGE; electrophoretic profiles
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It is generally recognized that urine, as a medium, is a
source of great number of diagnostic information. Determi-
nation of concentration of total urinary proteins, as well as
measuring of concentration of different urinary proteins
has been used to monitor kidney and urinary tract disease
for more than 150 years. The determination of total urinary
protein does not differentiate between glomerular and tubular
proteinuria. It has been demonstrated that different urinary
proteins carry different diagnostic information (8). So, uri-
nary concentration of high-molecular proteins, especially
albumin and immunoglobulin G, are the best markers for
assessment of glomerular function. Determination of uri-
nary concentration of low-molecular weight proteins, such
as α1-microglobulin, β2-microglobulin and retinol binding
protein (RBP) is recommended as potential markers for
evaluating function of renal proximal tubules (9). Measuring
of fractionary excretion of urinary sodium is used for
investigation the functional reabsorption capacity of the
distal segment of the nephron. Of all urinary enzymes, the
brush-border membrane enzyme leucine-aminopeptidase
(LAP) and the lysosomal N-acethyl-β-D-glucosaminidase
(NAG) were recommended as markers for investigation of
the structural integrity of renal proximal tubules (10).
In the recent years the accent is put on separation of
urinary proteins using high resolution electrophoretic
techniques, such as sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis (SDS-PAGE), capillary elec-
trophoresis and 2D-electrophoresis (11).
The results from great number of studies have shown
that SDS-PAGE is a method of choice for detection of early
renal lesions (12). It is also very attractive method, because
of its non-invasive nature, relatively low price and accuracy.
In the present work the patterns of urinary proteins in
healthy full-term infants during the first month of life were
investigated by SDS-PAGE, coupled with determination
of few parameters related to urinary protein excretion.
The purpose of this examination is to evaluate SDS-
PAGE profiles characteristic for healthy newborn infants;
this is the basis for further evaluation of SDS-PAGE in
assessment of glomerular and tubular function in conditions
in which renal function might be affected (such as hypoxic
ischemic encephalopathy, sepsis, nephrotoxic agents etc.).
Experimental
The present investigation was conducted on 20 healthy
full-term neonates with gestational ages ranging from 36
to 41 weeks (mean 38.2 ± 1.10 weeks).
Urinary samples excreted on day 3,7,14,21 and 28 after
birth were used for all examinations. Collection of urine
samples was made by using a collection bag placed over the
infants’ external genitals. All samples were taken promptly
to the laboratory and centrifuged on 3000 rpm for 15 minutes.
Total urinary proteins were determined by the Meule-
man`s method, using sulfosalicylic acid (13). Urinary cre-
atinine concentration was determined by Jaffe method (14).
Proteine/creatinine ratio (P/C) was calculated by dividing
the total urinary protein concentration with urinary con-
centration of creatinine.
Separation of urinary proteins was performed by hori-
zontal ultrathin pore gradient-dodecyl sulfate electro-
phoresis according to Görg et al. (15). Urinary samples were
neither diluted nor concentrated; 0.9 ml urine with 0.1 ml
sample buffer (1.5 M Tris/HCl, 10% SDS, pH 8.8) was incubat-
ed for 3 minutes in boiling water. SDS-polyacrylamide gra-
dient gels (4-22 %) were prepared by standard procedure in
dimensions 195 x 250 x 0.5 mm. SDS-PAGE worked at 5oC
for 2 hours on Multiphor II Unit, LKB (Brown, Sweden).
Pharmacia LKB low-molecular weight calibration proteins
were used for determination of molecular mass of separated
protein fractions.  Gels were stained with Coomassie Blue R-
250 and prepared in stable preparations.
Results and discussion
Results regarding the concentration of total urinary
proteins and P/C ratio in healthy full-term neonates on
days 3,7,14,21 and 28 of life are presented in Table 1.
The highest values for total urinary proteins in healthy
full-term neonates were detected in urinary samples
excreted on days 3 and 7 after birth with upper value of
405 mg/L and lowest values in samples excreted on days
21 and 28 of life with range between 10-50 mg/L.
The highest detected value for P/C ratio was detected
in urinary samples excreted on day 3 of life (480 mg/g cre-
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Healthy full-term neonates 
      
Parameters Day 3 Day 7 Day 14 Day 21 Day 28 
Total urinary proteins 156 130 32 29 25 
(mg/L) (10 - 405) (10 - 355) (10 – 120) (10 – 50) (10 – 50) 
P/C ratio 190 297 139 153 134 
(mg/g Creatinine) (30– 480) (38 – 460) (30 – 415) (80–248) (36 – 369 ) 
Table 1. Data (arithmetic mean and range) for total urinary proteins and P/C ratio on days 3,7,14,21 and 28 after birth 
in healthy full-term neonates (n=20)
Maked. farm. bilt., 51 (1,2)  9-14 (2005)
Evaluation of urinary proteins in healty full-term neonates by SDS-PAGE
atinine). The highest mean arithmetic value for P/C ratio
was detected in urine samples excreted on day 7 after birth
(297 mg/g creatinine). The differences in arithmetic means
for P/C ratio between day 3 and day 28 were not so expres-
sive like for the total urinary proteins concentration.
Fig.1, 2 and 3 present typical SDS-PAGE profiles
obtained from separation of urinary proteins in neonates,
included in conducted investigation. For electrophoretic
separation of each subject, five different urinary samples
(excreted on day 3,7,14,21 and 28 of life), with laterally
applicated protein markers, were used.
In 40 % of neonates (n=8) electrophoretic profiles were
characterized by the presence of proteins of mixed glomeru-
lar and tubular origin, detected in all five urinary samples.
The molecular weight of proteins were found to be distributed
over a wide range from 10 to 160 kDa. The intensity of frac-
tions was highest in urine sample excreted on days 3 and 7
and decreased thereafter. On day 3 the fractions with high-
est intensity were those with molecular weight of 67 kDa
(albumin) and molecular weight of about 30 kDa. One week
after birth the low molecular weight proteins predominated
because there was a substantial decrease in the excretion of
albumin and of high molecular weight proteins (Fig. 1).
In 20 % of neonates electrophoretic profiles were char-
acterized with presence of two faint fractions with molecular
weights of about 78 kDa and 90 kDa, and several intensive
and higher proportional low molecular weight fractions
(from 14 to 67 kDa). Fractions with molecular weight of
about 45 kDa, 30 kDa and 14 kDa were the most prominent
in urinary samples excreted on days 3 and 7 after birth. The
intensity of all fractions decreased in urinary samples ex-
creted on days 14, 21 and 28 after birth (Fig. 2).
In other 40% (n=8) of newborns in all urinary samples
only the presence of low molecular weight proteins (from 10-
67 kDa) was detected. The intensity of fractions was highest
in urinary samples excreted on days 3 and 7 after birth and
lowest in samples excreted on days 21 and 28 of life. In 7 of
neonates with this type of electrophoretic profile in samples
excreted 21 and 28 days after birth, the presence of only
albumin fraction was detected (Fig. 3).
Physiological proteinuria in adults is well known with
many studies regarding the determination of physiological
excretion of different proteins as well as separation of uri-
nary proteins with SDS-PAGE (16,17,18). There are also a
great number of studies related to quantitative changes in
some specific urinary proteins during the first month of life
and later in early infancy and older children (19, 20). There
are only a few reports in literature regarding the SDS-PAGE
electrophoretic profiles in healthy newborns (21-23).
In view of the lack of knowledge about physiological
proteinuria in neonates, the present study was undertaken to
11
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Fig. 1 Electrophoretic profiles of urinary proteins in healthy 
full-term neonate 3, 7, 14, 21 and 28 days 
after birth (A,B,C,D,E)
TP: total urinary proteins in mg/L, MW: molecular weight,
ST: Standard (Pharmacia LKB LMW calibration proteins)
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Fig. 2 Electrophoretic profiles of urinary proteins in healthy 
full-term neonate 3, 7, 14, 21 and 28 days 
after birth (A,B,C,D,E)
TP:  total urinary proteins in mg/L, MW: molecular weight,
ST: Standard (Pharmacia LKB LMW calibration proteins)
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obtain more information about the quantity and SDS-PAGE
profiles in these subjects.
The results obtained in our study for total urinary con-
centration have shown the highest values for TP excretion
detected on days 3 and 7 with range from 10-405 mg/L which
decrease thereafter with range from 10-50 mg/L on days 21
and 28. There are only a few reports related to TP concentra-
tion in neonates with different methods used for TP determi-
nation. The results in our study was in close agreement with
the findings from Miltenyi (22) who reported TP concentra-
tion between 95 - 455 mg/L in healthy full-term newborn
infants in the first month of life (7-30 days old).
In our study the determination of proteine-to creatinine
ratio was included, since the results of great number of stud-
ies of adults and children have shown that there is a strong
correlation between the urine P/C ratio, obtained in random
urine samples, and 24-hour urinary protein excretion correct-
ed for body–surface area (24-26). Thus with determination of
P/C ratio there is no need for 24-hour urine collection.
The highest value for P/C ratio in our study was detected
in urine samples excreted on day 3 after birth (480 mg/g
creatinine). In urine samples excreted on day 7 a similar
values for P/C was determined as in samples excreted on
day 3. In urinary samples excreted on day 14, 21 and 28 the
values for P/C ratio were lower with highest detected val-
ues of 415 mg/g creatinine. It is obvious that the differ-
ences between values for P/C ratios between urinary sam-
ples excreted on day 3 and samples excreted on days 7,14,
21 and 28 was no so expressive like the differences noticed
for otal protein concentration expressed in mg/L for the
same urinary samples. In urine samples excreted on day 3
the values for total protein concentration ranged between
10-405 mg/L and decreased rapidly thereafter in urine
samples excreted on day 14 (10-120 mg/L) with lowest values
in samples obtained on days 21 and 28 (10-50 mg/L). These
results confirmed the usefulness of urinary P/C ratio as a
better measure for urinary protein concentration, since it
is very obvious that dividing the total protein concentra-
tion by urinary creatinine concentration eliminates varia-
tions due to changing rates of urine output and provides a
measure independent of urine concentration.
The results obtained in our study for P/C ratio was in
close correlation with the results reported by other investi-
gators. In a study of Houser (26) the upper value for P/C ratio
found in 1 month old healthy infants was 500 mg/g creatinine,
which value is very similar to the values in our investigated
group of healthy neonates in first month of life.
The SDS-PAGE profiles obtained in our study from
investigation of the physiological proteinuria in healthy full-
term neonates reflected an incompletely developed renal
function. The presence of numerous bands distributed over the
broad range of molecular weights observed in urine samples
from neonates could be explained with transitory immaturity
of the glomerular filter and of the tubular protein reabsorbing
system of the newborn kidney. Apparently, the SDS-PAGE
profiles demonstrated that tubular protein handling normal-
izes later than the glomerular filtration of proteins.
The presence of protein fraction with molecular weight
of about 160 kDa, which according to molecular weight
belonged to imunoglobulin G, in some urinary samples of
neonates excreted on days 3 and 7 after birth (Fig. 1), could be
due to the fact that maternally derived antibodies are present
at birth.  Likewise, in the most of neonates prominent frac-
tion with molecular weight of about 45 kDa was detected in
urinary samples excreted on days 3 and 7 after birth, which
according to molecular weight belonged to α1- acid glyco-
protein, probably due to the acute phase response at birth.
Electrophoretic SDS-PAGE profiles, obtained in our
study, have shown that the intensity of albumin fraction (67
kDa) decreased during the neonatal period, which finding
could be supported by the results from quantitative determi-
nation of albumin in urine samples of neonates, excreted dur-
ing the first month of life, reported by Tsukahara et al (27).
The results from their study have shown that urinary albumin
decreased postnatally in healthy full-term neonates, while it
remained almost constant in preterm neonates. In sick pre-
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Fig. 3 Electrophoretic profiles of urinary proteins 
in healthy full-term neonate 
3, 7, 14, 21 and 28 days after birth (A,B,C,D,E)
TP: total urinary proteins in mg/L, 
MW: molecular weight,
ST:Standard (Pharmacia LKB LMW calibration proteins)
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terms who were depressed at birth and have respiratory failure,
urinary albumin was elevated during the first week, indicating
the presence of glomerular damage in this period.
In almost all urinary samples excreted on days 3, 7 and 14
after birth, intensive fraction with molecular weight about
30 kDa was detected, which according to molecular weight
belonged to α1-microglobulin. This findings is in close cor-
relation with the results from quantitative determination of
α1-microglobulin in urine samples of neonates, reported from
Tsukahara et al. (28). The results from their study have shown
high levels of α1-microglobulin in urine samples of neonates
excreted during the first two weeks of life, which declined
thereafter. This finding is due to the fact that α1-microglobu-
lin was found by many authors to be early marker of renal
tubular dysfunction, characterized by incomplete or inade-
quate reabsorption of low molecular weight proteins.
On SDS-PAGE profiles, obtained in our study, in a great
number of urine samples from neonates, excreted on days 3
and 7, the presence of protein fraction with molecular weight
of aproximately 12 kDa, with poor resolution, was found
(Fig. 1 and Fig. 3). According to molecular weight this frac-
tion belonged to β2-microglobulin, which finding could be
supported by results from quantitative determination of β2-
microglobulin in urine samples of neonates, during the first
month of life, reported by Tsukahara et al (27). The results from
their study have shown peak level on day 7 for β2-microglob-
ulin, both in term and preterm neonates, with trend towards
higher levels of β2-microglobulin with decreasing gestation,
showing that proximal tubular protein reabsorption decreases
with increasing degrees of prematurity. In sick preterms who
were depressed at birth and had respiratory failure, this
parameter was elevated during the first two weeks, indicating
the presence of tubular damage in this period.
Electrophoretic SDS-PAGE profiles in 16 of neonates
have shown the presence of visible, but with poor resolu-
tion protein fraction, with molecular weight of about 16 kDa.
This fraction was found in all urine samples excreted on
days 3,7 and 14 and in some urine samples excreted on
days 21 and 28 as a palide fraction. According to molecular
weight this fraction belongs to hemoglobin, which is the
fraction considered to be physiological, due to the short-
ened life of erythrocytes (22).
Karlsson and Kristoffer (21) investigated the urinary
protein pattern of pooled urine samples in the first year of
life. They found a tubular type proteinuria in a pooled urine
sample of eight 1- 4 week old newborns, while the protein
pattern of the pooled urine of eight 4-6 month old infants
was identical with the pattern of adults. Their study has
shown that tubular proteinuria disappears gradually during
the first years of life. Miltenye and his coworkers (22) frac-
tionated the urinary samples from 20 full-term neonates
(aged from 7 to 30 days) by sodium dodecyl sulphate gel
discelectrophoresis (7.5 % polyacrylamide gels stained
with 0.6 % Amido Black in 7 % acetic acid). The results
from their study have shown that proteinuria was predomi-
nantly tubular, although in some urine samples high mole-
cular weight protein fractions with molecular weight big-
ger than 100 000 kDa was detected, as well as middle mole-
cular weight fractions (89 000 and 80 000 kDa). They re-
ported also the presence of hemoglobinuria during the first
weeks of life.
The results obtained by analysis of the molecular
weights of urinary proteins in healthy newborns, separat-
ed by SDS-PAGE and stained with Coomassie Brilliant
Blue G-250, reported by Thanner et al. (23) confirmed the
findings of previous mentioned authors for presence of
glomerulo-tubular imbalance in early life. According to
the number of separated protein fractions and their rela-
tive concentration (expressed as percent of total protein
concentration) they concluded that proteinuria in healthy
full-term neonates is predominantly tubular and is due to
ineffective proximal tubular reabsorption of low molecu-
lar weight microproteins.
Conclusion
The results in the present study, related to examina-
tion of SDS-PAGE profiles in healthy full-term neonates,
confirmed the results obtained by other investigators that
electrophoretic profiles are a source of great number of
information about the physiological proteinuria frequently
detected in urine of neonates by screening methods. Know-
ledge of the modifications that occur in urinary protein
pattern due to age is therefore very important in order to
distinguish such modifications from those caused by other
factors. Investigation of SDS-PAGE profiles, coupled with
determination of few parameters related to protein excre-
tion, such as total urinary protein concentration and pro-
teine-to-creatinine ratio might be of great usefulness for
detection of early renal lesions in neonates, in clinical con-
dititions in which renal function is affected.
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Rezime
Evaluacija na urinarnite proteini kaj zdravi donoseni novorodeni so
primena na SDS-PAGE
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Klu~ni zborovi: Proteinurija, novorodeni, SDS-PAGE, elektroforetski profili
Izvr{eno e ispituvawe na vidot na izla~enite urinarni proteini kaj zdravi donoseni novorodeni so primena na
natrium dodecil sulfat poliakrilamid gel elektroforeza (SDS-PAGE), zaedno so odreduvawe na nekolku parametri
povrzani so ekskrecijata na urinarnite proteini.
Vo ispituvaweto bea vklu~eni 20 zdravi donoseni novorodeni deca. Kako materijal vo ispituvaweto bea koris-
teni po pet primeroci urina od sekoe novorodeno, izla~eni 3, 7, 14, 21 i 28 dena po ra|aweto. Opredeluvaweto na vkup-
nite proteini be{e napraveno so turbidimetriski metod so sulfosalicilna kiselina. Koncentracijata na krea-
tininot vo primerocite urina be{e opredeluvana so metodot po Jaffe. Separacijata na urinarnite proteini be{e
napravena so horizontalnata gradientna SDS-PAGE spored Görg.
Najvisoki vrednosti za vkupnite urinarni proteini i za protein/kreatinin soodnosot bea detektirani vo prime-
rocite urina izla~eni tretiot i sedmiot den po ra|aweto. Bea utvrdeni tri tipa na elektroforetski profili. Za
prviot tip elektroforetski profili be{e karakteristi~no prisustvoto na proteini od me{ano, glomerularno i
tubularno poteklo so molekularna masa od 10 do 160 kDa. Tipi~no za vtoriot tip elektroforetski profili be{e
prisustvoto na dve bledi frakcii so molekularna masa od 78 i 90 kDa, kako i pove}e intenzivni nisko molekularni
frakcii (14-67 kDa). Za tretiot tip elektroforetski profili karakteristi~no be{e prisustvoto samo na nisko
molekularni frakcii (10-67 kDa) vo site pet ispituvani primeroci urina. Mo`e da se zaklu~i deka naodite od
ispituvaweto ja izrazuvaat minlivata nezrelost na glomerularniot filter i na sistemot za reapsorbcija na tubular-
nite proteini kaj bubregot od novorodenoto. O~igledno e deka tubularnata funkcija se vospostavuva podocna vo
sporedba so glomerularnata filtracija na proteinite.
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Introduction
Recent developments in technology have presented
viable dosage alternatives for patients who may have diffi-
culty swallowing tablets. Traditional tablets and capsules
may be inconvenient or impractical for some patients.
Geriatric and pediatric patients experience difficulty in
swallowing conventional tablets which leads to poor pati-
ence compliance. This problem is overcomed with use of
drug delivery system known as orally disintegrating tablets.
These are novel types of tablets which disintegrate/dis-
solve/disperse in saliva for 60 seconds or less (1, 2, 3).
They are also suitable for the mentally ill, the bedridden
and patients who do not have easy access to water. The be-
nefits in terms of patience compliance, rapid onset of
action, possibility for increased bioavailability, and good
stability make these tablets popular as a dosage form of
choice in the current market (2). Orally disintegrating tab-
lets are suitable formulation for all active substances which
can be orally administered (3).
A pharmaceutical formulation is composed of several
composition factors and process variables. These factors and
variables not only affect the characteristic property of the
dosage form but also make it difficult to formulate. Formula-
tion experience with pharmaceutical preparation generally can
guide a formulation expert to select those variables that most
likely have an effect on those corresponding responses (4).
Traditional formulation designs were based on trial
and error. It is time-consuming, unreliable, costly and often
unsuccessful. The rapid development of statistical experi-
mental designs, optimisation techniques and computer
technologies provide an effective method for modelling
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Abstract
The objective of this study was to develop diazepam orally disintegrating tablets and to optimize tablets characteristics using
response surface methodology (RSM). Tablets were prepared by direct compression of mixture containing mannitol, copovidone,
crosspovidone flavor and lubricant. A full factorial design for 2 factors at 3 levels each was applied to investigate the influence of 2
formulation variables on the mechanical strength/hardness, the percent of friability, disintegration time and dissolution of the poorly
soluble active ingredient. The amounts of copovidone and crosspovidone were taken as independent variables. All data were analyzed
by using statistical program.
The results of multiple linear regression analysis revealed that for obtaining a rapidly disintegrating dosage form, tablets should be
prepared using an optimum concentration of crospovidone and copovidone. A contour plot is also presented to graphically represent the
effect of the independent variables on the tablet hardness, disintegration time, percentage friability and dissolution. A checkpoint batch
was also prepared to prove the validity of the evolved mathematical model. 
3 level factorial design allowed us to obtain ODT with rapid disintegration and dissolution of the active ingredient with desirable
properties of low tablet friability and appropriate mechanical strength (hardness) of the tablet.
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complicated multivariate drug formulations. Pharmaceuti-
cal formulation thus has been brought into a new era (5).
When a target is to evaluate one or more tablet pro-
perties, the experimenter can make use of a set of tools and
techniques known under experimental research methodo-
logy. In general, adopting such an experimental approach
means defining the problem which one is going to cope
with by determining the objectives, the possible constraints
in the component proportion and the response variables
under study (6).
Many statistical experimental designs have been reco-
gnized as useful techniques to optimize the process variables.
Different types of designs as screening, mixture, response
surface, have been used for preformulation evaluations (7, 8).
Response surface Methodology (RSM) is a widely
practiced approach in the development and optimization
of drug delivery devices. Based on the principal of design
of experiments (DoE), the methodology encompasses the
use of various types of experimental designs, generation
of polynomial equations, and mapping of the response
over the experimental domain to determine the optimum
formulation. The technique requires minimum experi-
mentation and time, thus providing to be far more effec-
tive and cost effective than the conventional methods of
formulating dosage forms. It is a collection of statistical
and mathematical techniques, useful for developing, im-
proving and optimizing processes (9, 10). It also has an im-
portant application in the design, development and for-
mulation of new products as well as in the improvement
of existing product designs. The basic components of res-
ponse surface methodology include experimental design,
regression analysis and optimisation algorithms which
are used to investigate the empirical relationship between
one or more measured responses and a number of inde-
pendent variables, with the ultimate goal of obtaining an
optimal problem solution. Also, interaction between diffe-
rent factors, which can influence the target responses,
may be detected (11, 12, 13).
The current study aims at developing and optimizing
an orally disintegrating tablet of diazepam using RSM.
Experimental
Materials
Diazepam was supplied from Fabbrica Italiana Sintetici -
Italy, Mannitol direct compressible grade from Merck KgA-
Germany, Copovidone and Crosspovidone from BASF KgA,
Germany and magnesium stearate from Mosselman, Belgium.
Methods
Experimental design
Response surface experimental design was used to opti-
mize and evaluate main effects, interaction effects, and quad-
ratic effects of the formulation ingredients on the percent of
friability, hardness, disintegration time and drug release. A 32
randomized full factorial design is suitable for exploring
response surfaces and constructing polynomial models (10).
In this design 2 factors were evaluated, each at 3 lev-
els, and experimental trials were performed at all 9 possi-
ble combinations. The amount of the binding agent, copo-
vidone (X1) and the amount of superdisintegrant, cros-
spovidone (X2) were selected as independent variables.
The percent of friability, hardness, disintegration time and
drug release were selected as dependent variables.
The composition of formulations of the factorial design
is shown in Table 1.
Preparation of Diazepam orally disintegrating tablets 
The raw materials were passed through a No.1.2 screen
prior mixing. Diazepam, copovidone and crosspovidone
were homogeneously blended with directly compressible
mannitol as a diluent. The mixture than was blended with
the fixed quantity of the lubricant magnesium stearate and
compressed into flat faced tablets (6 mm diameter) using
rotate tablet compression machine.
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1 2.6 0.2 3.0 0.50 1.0 92.70 
2 2.6 0.2 3.0 5.00 1.0 88.20 
3 2.6 0.2 3.0 0.50 5.0 88.70 
4 2.6 0.2 3.0 2.75 1.0 90.45 
5 2.6 0.2 3.0 0.50 3.0 90.70 
6 2.6 0.2 3.0 2.75 3.0 88.45 
7 2.6 0.2 3.0 5.00 5.0 84.20 
8 2.6 0.2 3.0 5.00 3.0 86.20 
9 2.6 0.2 3.0 2.75 5.0 86.45 
Table 1. Responce surface experimental design
Orally disintegrating tablet: formulation design and optimisation using Response Surface Methodology
Evaluation of tablet properties
Hardness /Mechanical strength
The tablet hardness was measured by hardness tester
(VanKelVK200 ,USA)
Percent Friability
The friability of tablets was determined using friabili-
ty tester (VanKel, USP). The method of determination was
according to USP28 method. The percent friability was
obtained from 20-tablet sample.
Disintegration Time
The disintegration time was measured by using accord-
ing USP 28 method for disintegration of tablets (VanKel 6-
Basket System,USP)with purified water at 37 oC as disin-
tegration medium. The mean and standard deviation were
calculated from six determinations.
Percent Drug Release
Dissolution studies were performed employing USP
28 paddle method (VanKel Dissolution tester, VK-700,
USA), 900 ml of 0.1mol/l HCl as dissolution medium at
50 rpm. The samples were analyzed using HPLC method
(USP28).
Tablet assay
The tablets were assayed for drug content according
USP 28 monograph for Diazepam tablets (Varian, HPLC
system UV/vis variable wavelength detector, USA).
Statistical analysis
The data obtained from the evaluation of the tablet
characteristics were analyzed using Statgraphics® plus,
Windows software program (Version 5.1, USA).
Results and discussion
Tablet evaluation
All nine formulations of the experimental response sur-
face design were prepared as different combinations of inde-
pendent variables, copovidone (0.5-5 %) and crosspovidone
(1-5 %) and the following parameters were analyzed: hard-
ness, tensile strength, friability, disintegration and dissolu-
tion of the tablets.
The results of analysis of dependent variables- respon-
ses for each formulation are presented in Table 2.
The expressed results are mean values, for the hardness
and friability determination of 20 tablets, disintegration of
12 and dissolution of 6 tablets.
During the preparation of the tablets, lower mechani-
cal strength and increased friability for the series 1, 3, 5 under
the applied pressure during tabletting were gained (RS
design, quantity of the binding agent copovidone 0.5 %).
Adequately, the friability of these formulations was not
within the required limit, as described in USP28.
The hardness and friability were improved with incre-
ase of the concentration of the dry binder in the formula-
tions. Complete release of diazepam from the prepared for-
mulations was noticed after 20 and/or 30 min, showing dif-
ferences in drug release rates due to different composition
among series within the first 10 and 20 min. Disintegration
of the tablets showing appropriate mechanical strength was
fastest for series 9 (combination with 2.75 % of copovidone
and 5 % of crosspovidone). However, the results given in
Table 2 express that percent of drug release and the time of
disintegration are not parameters that could be easily evalu-
ated (followed) and are complex functions which mathe-
matical expression and dependence (effect) of independent
variable will be obtained from the experimental design.
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 (sec) 10 min 20 min 30 min 
1 1 0.30 1.050 20 95.80 97.02 complete diss.  
2 5.5 1.80 0.062 100 95.08 98.30 complete diss.  
3 1 0.31 1.163 10 95.53 95.08 complete diss.  
4 4 1.27 0.078 55 96.20 97.20 complete diss.  
5 1 0.31 1.091 12 94.68 97.30 complete diss.  
6 4 1.28 0.085 19 94.30 95.60 complete diss.  
7 5.5 1.80 0.051 40 93.16 95.06 complete diss.  
8 5.5 1.81 0.055 60 93.89 97.41 complete diss.  
9 4 1.27 0.085 12 93.11 96.15 complete di ss. 
Table 2. Results of the determination of the dependent variables for each series
a Y1 - Hardness         b Y2 - Tensile strength          c Y3 - Friability          d Y4 - Disintegratione           Y5 - Dissolution of diazepam in 0.1 mol/l HCl
Factorial design
Hardness of tablets
The relationship between the hardness of the tablets
and the independent variables is presented in Fig. 1.
The standardized pareto chart at Fig. 1. depicts the main
effect of the independent variable on the tablet hardness.
The length of each bar in the graph indicates the effect of
these factors and the level of their responses. From Figure 1
it can be interfered that the factor X1 has a main effect on
the response Y1. Factors X2, X1X2, X2X2 did not show
significant effects on the Y1 response (the hardness of the
tablets). With excluding of the factors which do not have
significant effect on the response, the mathematical rela-
tionship in the form of polynomial equation for the meas-
ured response Y1 would be:
Y1=0.75+1*X1   (Eq. 1)
Results presented in Fig. 1 and Eq. 1 show that the
most significant effect on the hardness of the tablets has the
binding agent copovidone, without the significant influ-
ence of the interaction between the factors i.e. between the
binding and disintegrating agent.
Also, Fig. 2 illustrates that the quantity of the binding
agent is a factor which shows significant and linear effect
on the hardness of the tablets (when applied constant
punch pressure).
Friability of the tablets
The mathematical relationship in the form of polyno-
mial equation for the measured response, Y3 is listed below:
Y3=1.37834-0.750494*X1+0.0280278*X2+0.0979753*
X1^2-0.00688889*X1X2 (Eq.2)
The polynomial equation represents the quantitative
effect of process variables (X1 and X2) and their interac-
tion on the response Y3. The values of coefficients X1
and X2 are related to the effect of these variables on the
response Y3. A positive value represents an effect that
favor the optimisation, while a negative value indicates
an antagonistic effect.
The main effect on the independent variables on the
dependent variables was further investigated using a pare-
to chart (Fig. 3) and interaction plot (Fig. 4). Also, the relation-
ship between the dependent and independent variables



























































Fig. 2. Response surface plots showing the effect 
of independent variable X1 (copovidone) on response 
Y1 (hardness of the tablets)
Fig. 3. Standard pareto chart showing the effects 
of independent variables X1 (copovidone) and 
X2 (crosspovidone) and their combined effects 
on the response Y3 (friability of the tablet) 
Fig. 4. Interaction plot showing the effects of interactions 










Fig. 1. Standard pareto chart showing the effects 
of independent variables X1 (copovidone) i X2 
(crosspovidone) and their combined effects 
on the response Y1 (hardness of the tablets)  
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was further elucidated using response surface plots (Fig.
5). Fig. 3 depicts the main effect of the independent vari-
able on the friability of the formulations.
From Figs. 3 and 4 it can be interfered that the factors:
X1, X1X1 (quadratic effect of copovidone), X1X2 (inter-
action effect of copovodone and crosspovidone) and X2
have a significant effect on the response Y3.
Fig. 5 further explains the effect of X1 and X2 ratios on
the friability of the tablets. From response surface plots it is
clear that the ratio of copovidone and crosspovidone has a
major effect on determining friability of formulations.
Figure 5 shows that at lower concentrations of copovidone
the friability increases.
Disintegration of tablets
Fig. 6 represents the influence of independent variab-
les on disintegration. 
Mathematical relationship in a form of polynomial
equation is listed below:
Y4=19.2428+7.36214*X1-1.77778*X2+2.30453*
X1^2-2.77778*X1*X2 (Eq.3)
The main effect on the disintegration time depend on
copovidone and crosspovidone quantity in the formula-
tion, interaction between the binding and disintegrating
agent and quadratic effect of copovidone. Decreasing the
percentage of copovidone and increasing the percentage
of crosspovidone decreases the time of disintegration of the
tablets (influence of the copovidone/crosspovidone inter-






































Fig. 5. Response surface plots showing the effect 
of independent variables, varying ratio of 
(X1) copovidone and (X2) crosspovidone 
on response Y3 (friability of the tablet)
Fig. 6. Standard pareto chart showing the effects 
of independent variables X1 (copovidone) and 
X2 (crosspovidone) and their combined effects 


















































Fig. 8. Response surface plots showing the effect 
of independent variables, varying ratio of 
(X1) copovidone and (X2) crosspovidone 









Fig. 9. Standard pareto chart showing the effects 
of independent variables X1 (copovidone) 
and X2 (crosspovidone) and their combined effects 
on the response Y5 (dissolution of diazepam 
in 0.1mol/l HCl, for 30 minutes) 
Fig. 7. Interaction plot showing the effects of interactions 
between the factors on the disintegration of the tablets
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Adequately, at level of 1 % of incorporated disinte-
grating agent, increasing quantity of copovidone will sig-
nificantly increase the value of the disintegration time for
the prepared formulations (Fig. 8 shows response surface
plots showing the effect copovidone  and crosspovidone
on disintegration).
Drug dissolution
Dissolution of the active ingredient in orally disinte-
grating tablets starts in the mouth after the fast disintegra-
tion where the pH is approx. 6.8 (6.4-7.2). After the swal-
lowing of the granules or the primary particles the drug
dissolution continues at pH approximately 1.5 and the ab-
sorption of the released drug depends on the basic dissolu-
tion of the active ingredient and its permeability through the
membranes. Diazepam is classified in the second group of
biopharmaceutical classification system i.e. is practically
insoluble substance at pH 6.8 or at basic pH and showing
good permeability through the biological membranes.
Except better patient compliance, fast dispersible/disinte-
gration tablet means avoiding the factors of the disintegra-
tion process on the efficacy of the tablet formulation. As
diazepam dissolution rate decreases at basic pH, its imme-
diate availability in primary particles for dissolution after
reaching the gaster and pH 1.5 might contribute to its bet-
ter availability for absorption. 
The Response Surface design shows that drug release in
acidic medium is influenced only by the quantity of disinte-
grating agent, which is represented in Fig. 9 and Fig. 10 where
factor X2 shows the main significant effect.
Conclusion
Optimization of Diazepam ODT using response sur-
face full factorial design was performed.
The quantity and the ratio of independent variables
showed significant effects on the tablet characteristics.
The most significant effect on the hardness of the
tablets shows the binding agent copovidone. Increasing the
quantity of copovidone increases the hardness of the tablets.
The most significant effect on the friability of the
tablets has copovidone, although effect on the friability due
to the interaction between copovidone and crosspovidone
is also present. With increasing the content of copovidone
the percent of friability of the tablets decreases.
The quantity of the copovidone and crosspovidone
presents the main effect on the tablet disintegration. Inter-
action among copovidone and crosspovidone shows sig-
nificant effect on the disintegration process, also. Incre-
asing the quantity of crosspovidone and decreasing the
quantity of copovidone decreases the time of disintegra-
tion of the tablets. Faster disintegration of diazepam tablet
means that complete drug release will be achieved in
medium where the active substance has a good solubility
i.e. the influence of the disintegration time of the pharma-
ceutical dosage form on the dissolution time and of the
active component  is completely  avoided and the dissolu-
tion rate and time will depend only on the characteristics
of the active ingredient, which if needed might be modi-
fied as well. Based on the quantitative effect of the poly-
nomial equations generated by RSM, the optimum formu-
lation from RS design could be formulation with adequate
hardness, friability and disintegration time less than 20
sec. Such formulation/s contains  copovidone 2.75 % and






























Fig. 10. Response surface plots showing the effect 
of independent variables, varying ratio 
of (X1) copovidone  and (X2) crosspovidone 
on response Y5 (dissolution of diazepam 
in 0.1 mol/l HCl)
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Rezime
Peroralna disperzibilna tableta: Formulaciski dizajn i 
optimizacija so primena na Response Surface metodologija
Biljana Nestorovska-\o{evska*, Marija Glava{-Dodov, Katerina Gora~inova
Institut za farmacevtska tehnologija i biofarmacija, Farmacevtski fakultet,
Univerzitet „Sv. Kiril i Metodij“, Vodwanska 17, 1000 Skopje, Makedonija
Klu~ni zborovi: peroralna disperzibilna tableta, eksperimantalen dizajn, response surface metodologija.
Cel na ovoj trud be{e razvoj na diazepam peroralna disperzibilna tableta i optimizacija na karakteristikite
na tabletata so primena na response surface metodologijata. Tabletite bea podgotveni so direktna kompresija na
me{avina od manitol, kopovidon, krospovidon, aroma i sredstvo za lubrikacija.
Be{e primenet full factorial dizajn na dva faktori na formulacijata, sekoj postaven na 3 nivoa, so cel da se ispi-
ta efektot na dvata promenlivi faktori na formulacijata vrz mehani~kata jakost/cvrstinata, procentot na frija-
bilnost, vremeto na dezintegracija na tabletite i disolucijata na te{ko rastvorlivata aktivna komponenta. Kako
nezavisni promenlivi bea zemeni koli~inite na kopovidon i krospovidon. Dobienite rezultati bea analizirani so
primena na soodvetna statisti~ka programa.
Rezultatite od multipnata regresija poka`aa deka za da se dobie dozirana forma so mnogu brza dezintegracija,
tabletite treba da sodr`at optimalna koncentracija na kopovidon i krospovidon. 
Efektot na nezavisnite promenlivi na cvrstinata na tabletata, vremeto na dezintegracija, procentot na frija-
bilnost i disolucijata grafi~ki e pretstaven so soodvetni konturni nacrti. Za da se prika`e validnosta na prime-
netiot matemati~ki model be{e podgotvena i kontrolna serija.
Faktorijalniot dizajn na 3 nivoa ovozmo`i da se dobie peroralna disperzibilna tableta so mnogu brza dezinte-
gracija i disolucija na aktivnata komponenta, so zadovolitelna frijabilnost i soodvetna mehani~ka jakost (cvrsti-
na) na tabletite.
Introduction
Hydrochlorothiazide is a thiazide diuretic drug (Fig.
1), which is used in treatment of hypertension, either alone
or together with other agents, it is effective in treatment of
congestive heart failure and hepatic disorders. In medical
practice, it is mostly used in a conventional tablet form in
dose of 25 to 250 mg (1).
Several investigations have been performed for deter-
mination of hydrochlorothiazide in urine by high-perfor-
mance liquid chromatography (HPLC) with UV detection
and electrochemical detection. Zendelovska and Stafilov
(2) published a review of HPLC methods for determination
of diuretics in biological fluids including procedures for
sample preparation. Liquid-liquid extraction with different
organic solvents is mostly used for determination of hydro-
chlorothiazide in urine. But, in this way, separation of hydro-
chlorothiazide from interferential components is not achieved
and recovery values are poor. Cooper and coworkers (3)
suggested a liquid-liquid extraction of hydrochlorothiazide
from urine and serum by ethyl acetate and back extraction with
sodium hydroxide, but recovery values were 91,5 ± 2,5 %.
Shiu and coworkers (4) proposed a liquid-liquid extraction
of hydrochlorothiazide from urine with ethyl acetate, but
again, the recovery values are ranged from 62.2 to 80.7 %.
Alton and coworkers (5) have also used ethyl acetate for
extraction of hydrochlorothiazide from urine.
On the other hand, Domingo and coworkers (6) used
micellar liquid chromatography for determination of
hydrochlorothiazide in urine by direct injection of sample
in the chromatographic system without any sample pre-
treatment. Zendelovska and coworkers (7) developed a
solid-phase extraction method for determination of hydro-
chlorothiazide in human plasma. Papadoyannis and co-
workers (8, 9) have performed a chromatographic deter-
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A simple, rapid and precise HPLC method has been developed for the assay of hydrochlorothiazide in urine. The clean-up of the
urine samples was carried out by solid-phase extraction using HLB cartridges. Extraction recovery was 94.00-100.28 %. HPLC separa-
tion was performed with isocratic elution on Hypersil BDS C18 column (100 x 4.0 mm I.D., 3 µm particle size) protected with appro-
priate guard column. The mobile phase was 18 % acetonitrile and 0.025 mol/L solution of KH2PO4, pH 4 at flow rate of 0.3 mL/min.
Detection of the substances was performed at 220 nm. The calibration curves were linear in the range of 2-50 µg/mL. The developed
method is validated by checking its accuracy, precision and stability. The detection limit is 2 µg/mL hydrochlorothiazide. The method is
proved to be convenient for routine analysis of hydrochlorothiazide in urine.
Keywords: Hydrochlorothiazide, urine, solid-phase extraction, HPLC
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Fig. 1. Structure of hydrochlorothiazide
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mination of cephalosporin antibiotics in biological fluids
and pharmaceuticals using hydrochlorothiazide as an in-
ternal standard. The confirmation technique most widely
used is GC/MS, which requires methylation of the amino-
sulfonyl group followed by GC/MS measurement (10).
The purpose of this study was to develop and validate
a liquid chromatographic method with UV detection suit-
able for the determination of hydrochlorothiazide in urine.
A new solid-phase extraction method was developed using
HLB cartridges. This is a convenient method for separa-
tion and concentration of the analyzed drug and elimina-
tion of urine interferences, because of its efficiency and
rapid sample preparation. The method was validated by
evaluating the recovery, selectivity, linearity, precision and
accuracy. Finally, the method was used for determination
of hydrochlorothiazide in urine samples from patients.
Experimental
2.1. Materials and reagents
Hydrochlorothiazide was kindly provided from Chang-
zhou Pharmaceutical Factory (China). Acetonitrile, metha-
nol, phosphoric acid, and potassium dihydrogen phosphate
were from Merck (Darmstadt, Germany). All solvents used
were of HPLC grade. HPLC column was purchased from
Hewlett Packard and cartridges for solid-phase extraction
were purchased from Waters.
2.2. Preparation of standards
Stock solution of hydrochlorothiazide was prepared at
concentration of 2 mg/mL by dissolving appropriate amounts
of hydrochlorothiazide in methanol. The working solu-
tions were prepared by diluting appropriate portions of this
solution with redistilled water and stored at 4°C.
2.3. Instrumentation and HPLC analysis
Analysis of hydrochlorothiazide was carried out with
a Varian HPLC system equipped with a ternary pump
Model 9012 and UV Diode Array Detector Model 9065.
Satisfactory results (peak shape and run time) were obta-
ined with Hypersil BDS C18 column (100 x 4.0 mm I.D.,
3 µm particle size) protected with appropriate guard col-
umn. A mobile phase consisting of solution of KH2PO4
with concentration 0.025 mol/L (pH 4) and 18 % acetoni-
trile was found to give the best results. Isocratic elution
was performed with flow rate of 0.3 mL/min at ambient
temperature. Elution was monitored in the whole UV
region and the best detection was achieved on wavelength
of 220 nm.
Solid-phase extraction was performed with the device
(SPE) Visiprep™ from Supelco.
2.4. Sample preparation
Urine samples were collected from healthy volunteers
and stored at -20°C. After thawing, samples were spiked
daily with working solutions of hydrochlorothiazide. Several
cartridges with different stationary phases for SPE were
tested: LiChrolut RP-18 (Merck), LC-18 (Supelco) and Oasis
HLB (Waters). Best results for isolation of hydrochloroth-
iazide were obtained when SPE was performed with Oasis
HLB cartridges.
Before extraction, 1 mL of urine sample was buffered
with 1 mL of 0.1 mol/L KH2PO4 solution, pH 9. The car-
tridges were conditioned with 1 mL methanol and 1 mL re-
distilled water. The buffered urine was introduced into the
cartridge. 1 mL of redistilled water was used to rinse the
cartridge and remove the interfering components. Elution
was performed with 1 mL methanol. The eluate was evap-
orated to dryness under air for about 15 min at 40-45°C.
Reconstitution was performed with 200 µL mobile phase
and 20 µL sample was injected into the HPLC system.
2.5. Calibration standards 
Linear regression analysis was performed. Typical ca-
libration curves were constructed with five blank urine
samples spiked with appropriate amounts of the standard
solution of hydrochlorothiazide. The calibration range was
2-50 µg/mL of hydrochlorothiazide in urine. Three quality
control standards containing 7, 15 and 30 µg/mL hydro-
chlorothiazide in urine were used for precision and accu-
racy measurements.
Results and discussion 
3.1. Method development
In order to develop a convenient, simple and rapid
HPLC method for quantitative determination of hydro-
chlorothiazide in urine, several HPLC method variables
with respect to their effect on the place and shape on the
peak of hydrochlorothiazide, were investigated. The opti-
mization of the HPLC conditions was performed for hydro-
chlorothiazide and cefotaxime, which was tested as an inter-
nal standard. Symmetrical shape of the peaks and relatively
short time for analysis were obtained when separation was
performed on Hypersil BDS   C18 column (100 x 4.0 mm
I.D., 3 µm particle size) protected with appropriate guard
column with flow rate of 0.3 mL/min flow rate. The elution
was monitored in the whole UV region and the wavelength
of 220 nm exhibited the best detection of hydrochloroth-
iazide due to an absorption maximum at this wavelength.
Series of mobile phases with variable content of the
organic modifier acetonitrile in range from 15 to 30 % were
prepared in order to investigate its effect on hydrochloro-
HPLC determination of hydrochlorothiazide in urine after solid-phase extraction
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thiazide and cefotaxime retention. Satisfactory results (peak
shape, short retention time) were obtained when the volume
fraction of acetonitrile in the mobile phase was 18 %.
Additionally, the effect of the buffer concentration on
analyte retention was investigated in the concentration range
from 0.0125 to 0.0500 mol/L. Best results were achieved with
solution of KH2PO4 with concentration of 0.025 mol/L. The
subsequent increasing of the buffer concentration caused
increase in analysis time. Therefore, all following investiga-
tions were performed with a mobile phase, containing KH2PO4
with concentration of 0.025 mol/L and 18 % acetonitrile.
The effect of the pH value on the hydrochlorothiazide and
cefotaxime retention was also checked by elution with mobile
phases with pH in the range from 2.2 to 4.5. A mobile phase
with pH 4 provided a short analysis time and good peak shape.
Finally, the effect of temperature on retention of the
analyzed component was checked in the range from 20 to
50°C. The obtained results showed that temperature does
not affect the peak shape and analysis time significantly,
so ambient temperature was chosen for all investigations.  
From these data it was established that the best results
(satisfactory retention, acceptable runtime less than 6.5
min.) were obtained using mobile phase consisting of 18 %
acetonitrile in solution of KH2PO4 with concentration of
0.025 mol/L and pH 4. The retention time of hydrochloro-
thiazide is 5.8 min and 4.0 min for cefotaxime. Typical
chromatogram obtained from standard solution of hydro-
chlorothiazide and cefotaxime produced by the developed
HPLC method is shown in Fig. 2.
Calibration diagram was constructed for establishing
the dependence of the peak area of hydrochlorothiazide
and concentration. The obtained linear dependence of
peak area of hydrochlorothiazide and mass concentration
of hydrochlorothiazide in pure solutions, with correlation
coefficient (0.9999) is the following:
Area(H) = 194029 · γ(H) (µg/mL) + 297658
As previously said, several cartridges for solid-phase
extraction (LiChrolut RP-18 (Merck), LC-18 (Supelco) i
Oasis HLB (Waters)) were tested in order to obtain satis-
factory values for recovery of hydrochlorothiazide from
urine samples. Results from this investigation show satis-
factory values for recovery of hydrochlorothiazide when
urine samples were extracted on Oasis HLB (Waters) car-
tridges. The values obtained for recovery of hydrochloro-
thiazide ranged from 94.00 to 100.28 %. The chromato-
graphic peak is sharp, with relatively symmetric shape with
small tailing, well separated form the matrix components
present in the urine (Fig. 3). In this phase, cefotaxime was
excluded as a possible internal standard because of its
poor separation from the endogenous compounds from
urine and the method was then validated using HLB car-
triges for sample preparation and the optimized HPLC
conditions for measurement using calibration with an
external standard of hydrochlorothiazide.
Separation of interferential components from matrix
was not achieved with application of RP-18 cartridges for
solid-phase extraction of hydrochlorothiazide and a loss
of analyzed component during the washing step was noticed.
LC-18 cartridges were not convenient for separation of the
analyzed component from matrix components present in
urine. Endogenous components from urine were not elim-
inated and the chromatographic peak of hydrochlorothia-
zide was overlapped with chromatographic peaks of the
interferential endogenous components.
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Fig. 2. Chromatogram of standard solution of hydrochlorothiazide
(8 µg/mL) and cefotaxime (8 µg/mL)
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Fig. 3. Chromatogram of urine sample spiked with 
hydrochlorothiazide (25 µg/mL) obtained 
after SPE on HLB columns
Violeta Ivanova, Dragica Zendelovska and Marina Stefova
3.2. Method validation
3.2.1. Linearity 
Linearity was tested in 3 days at five concentration
points ranging from 2 to 50 ?g/mL of hydrochlorothiazide.
The following values for the slope, intercept, and correla-
tion coefficient were obtained:
Slope = 184199.4          Intercept =- 46177.9          R2 = 0.99977
3.2.2. Accuracy and precision 
Intra-and inter-day precision and accuracy were deter-
mined by measuring urine quality control samples at low
(7 µg/mL), middle (15 µg/mL) and high (30 µg/mL) con-
centration levels of hydrochlorothiazide. An indication of
accuracy was based on calculation of the relative error of
the mean observed concentration compared with the nomi-
nal concentration. Precision was expressed as relative
standard deviation (RSD). Obtained results are presented
in Table 1.
Relative errors ranged from 0.26 to 9.28 %, and rela-
tive standard deviation from 1.01 to 5.16 %. The obtained
results indicated good precision and accuracy of the devel-
oped method.
3.2.4. Limit of quantification (LOQ)
The limit of quantification is defined as the lowest con-
centration of hydrochlorothiazide which can be measured
with an error less than 20 %. The LOQ was determinated
using the lowest calibration standard in five different ana-
lytical days. The RSD value of 7.57 % and a relative error
less than 10 % confirmed that the hydrochlorothiazide con-
centration of 2 µg/mL in urine can be accepted as LOQ. 
3.2.5. Stability of hydrochlorothiazide in urine samples
The stability of hydrochlorothiazide in urine samples
was investigated with spiked samples at two different con-
centration levels prepared in duplicate. Spiked samples
were analyzed after different storage conditions: immedi-
ately, after staying for 2 and 24 hours at room temperature,
after one and two freeze/thaw cycles and after 1 month
stored at -20°C. The obtained results form these investiga-
tions are shown in Table 2.
The obtained results show that relative errors are
between 0.28 to 5.59 %, which means that, hydrochloroth-
iazide added in urine samples is stable under different sto-
rage conditions.
3.2.6. Ruggedness of the method 
Ruggedness of the method was checked by employing
the proposed HPLC method with slightly changed pH val-
ue of the mobile phase and by using slightly changed
detection wavelength. The relative error was calculated by
comparing the results obtained with the optimized condi-
tions and the ones obtained with the slightly changed
parameters (pH value of the mobile phase from 3.7 to 4.3,
detection wavelength 215 and 224 nm). For this test, a
standard solution with medium concentration of hydro-
chlorothiazide (7 µg/mL) was directly injected into the
HPLC system. Results are present in Table 3.
The relative errors between 0.08 and 4.77 % indicat-
ing ruggedness of the developed HPLC method when using
Maced. pharm. bull., 51, (1,2) 23-28 (2005)
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 Intraday precision and accuracy  Interday precision and accuracy  




n=6 RSD (%) 
er 
(%) 
7 µg/mL 6.84 1.03 -2.24 6.86 5.16 -1.90 
15 µg/mL 15.03 1.01 0.22 15.28 4.42 1.85 
30 µg/mL 29.96 2.77 -0.13 30.05 3.61 0.16 











Immediately 6.98 - 0.28 29.48 - 1.73 
After 2h 6.72 - 3.72 30.95 4.98 
After 24h 6.85 - 1.86 29.42 - 0.20 
Cycle 1 7.02 0.57 31.12 5.56 
Cycle  2 7.23 3.58 27.83 - 5.59 
After 1 month 7.13 2.14 30.19 2.41 
Table 2. Stability of hydrochlorothiazide in urine
Sample 7 µg/mL  
 <Area> er(%) 
220 nm 2058948  
215 nm 1999378 - 2.89 
224 nm 2137594 3.82 
pH 2.5 2058948  
pH 2.2 2075528.3  0.81 
pH 2.8 1990904 - 3.30 
Table 3. Ruggedness of the method for hydrochlorothiazide 
at slightly varied pH values and detection wavelengths
HPLC determination of hydrochlorothiazide in urine after solid-phase extraction
Maked. farm. bilt., 51, (1,2)  23-28 (2005)
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slightly variable pH values of the mobile phase. The results
presented in Table 3, show that little changes in the detec-
tion wavelength produce relative errors in the range from
1.09 to 4.87 % which confirms the ruggedness of the SPE
method developed for solid-phase extraction of hydro-
chlorothiazide.
The developed HPLC method after solid-phase extrac-
tion of hydrochlorothiazide from urine was used for analy-
sis of patient urine samples after oral administration of the
analyzed drug. Typical chromatograms obtained from
urine samples prepared according to the developed proce-
dure for sample preparation are shown in Fig. 4.
Conclusion
The HPLC method including solid-phase extraction
for sample preparation is simple, rapid and convenient for
determination of hydrochlorothiazide in urine samples.
HPLC conditions are optimized as well as the sample
preparation procedure. Different SPE cartridges for separa-
tion and concentration of hydrochlorothiazide were tested
and best results are obtained with HLB cartridges. SPE
conditions with HLB cartriges are optimized for separation
of hydrochlorothiazide and efficient clean up of the com-
plex biological matrix and high recovery of the investigat-
ed drug is achieved. The validation data demonstrate good
precision and accuracy, which proves the reliability of the
proposed method. Finally, this method is suitable for iden-
tification and quantification of hydrochlorothiazide in
urine and it can be used in pharmacological studies. 
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Fig. 4 Chromatograms obtained after SPE of: 
1 - blank sample, 2 - spiked urine containing 25 µg/mL
hydrochlorothiazide and 3 - patient urine sample 
(H - hydrochlorothiazide)
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Rezime
HPCL opredeluvawe na hidrohlortiazid vo urina 
posle cvrstofazna estrakcija
Violeta Ivanova1, Dragica Zendelovska2, Marina Stefova1*
1Institut za hemija, Prirodno-matemati~ki fakultet,
2Institut za pretklini~ka i klini~ka farmakologija i toksikologija, 
Medicinski fakultet, Univerzitet „Sv. Kiril i Mettodij“, Skopje, Republika Makedonija
Klu~ni zborovi: hidrohlortiazid, urina, cvrstofazna, ekstrakcija, HPCL.
Razvien e ednostaven, brz i precizen HPCL metod za opredeluvawe na sodr`ina na hidrohlortiazid vo urina.
Podgotovkata na primerocite od urina i nivno pro~istuvawe e napraveno so HLB koloni od cvrstofazna ekstrakci-
ja. Prinosot po pre~istuvaweto e 94,00 – 100,28%. Razdvojuuvaweto na komponentite e napraveno so iskratsko eluira-
we na Hypersil BDS C18 kolona (100 h 4,0 mm, I.D., 3 µm golemina na ~esti~ki) so soodvetna predkolona. Mobilna faza
vo sostav: 18% acetonitril i 0,02 mol/L rastvor na KH2PO4, pH 4 i protok na 0,3 mL/min. Detekcijata na supstancite e
izvr{ena na 220 nm. Kalibracionata kriva poka`uva linearnost vo opsegot od 2-50 µg/mL. Metodot e validiran so pro-
verka na to~nost, preciznost i soodvetnost na sistemot. Limitot na detekcija e 2µg/mL hidrohlortiazid. Ovoj metod
ve}e ja ima doka`ano svojata ednostavnost i upotreblivost vo rutinska analiza na hidrohlortiazid.
Introduction
Helichrysum species (Asteraceae) have been well known
plants in folk medicine for hundreds of years. One of them,
Helichrysum plicatum DC. is widely distributed throughout
the whole territory of Balkan Peninsula. Water extract (infuse)
of this plant have been used for treatment of gastric and
hepatic disorders, usually in combination with other plants
with similar effects (1). Phytochemical screening (HPLC) of
the Helichrysum plicatum from Macedonia proved the pres-
ence of apigenin and naringenin as free aglycones and glyco-
sides of apigenin, naringenin, quercetin and kaempferol in
the flowers as well as quercetin and luteolin glycosides and
free luteolin in stems and leaves (2). Its antioxidant and scave-
nging properties have not been studied previously. Among
phytochemicals, flavonoids deserve a special mention due
to their free radical scavenging activities and in vivo biolog-
ical activities that are being investigated by many rese-
archers (3,4,5,6,7). The goal of research on antioxidative
characteristics of plant extracts is to discover a potential
replacement for synthetic antioxidants (BHT, BHA), which
cause unwanted processes after prolonged used.
The evaluation of plant extracts antioxidant capacity is
not easy task, as many methods can be used to determine this
activity, and substrates, conditions, analytical methods, and
concentrations can affect the estimated activity (8). This paper
reports a study in which antioxidative activity of methanolic,
ethyl acetate, and after hydrolysis extracts are tested. This
effect was followed by three complementary in vitro meth-
ods: evaluation the free radical scavenging capacity (DPPH
method) (9), inhibition of hydroxyl radicals production (10)
and protection of β-carotene-linoleic acid system (11).
Materials and Methods
Plant material
The aerial parts of Helichrysum plicatum DC. were
collected on the Golac Mountain, Eastern Macedonia, in
the flowering period of the plant, during the summer of
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Abstract
The present study describes the ability of different extracts of H. plicatum obtained from flowers, stems and leaves, to act as natural
antioxidants in different in vitro experimental models in which free radical reactions are involved: inhibition of DPPH (1,1-diphenyl-2-
picrylhydrazyl) radical, inhibition of hydroxyl radicals and protection of β-carotene-linoleic acid model system.
Investigate extracts showed radical scavenging activity with IC50 from 6 to 11 mg/ml. The extracts are capable to reacting with OH•
radical with inhibition of its production ranged between 33-58%. The high preventive activity against the bleaching of beta-carotene
(15-49% of initial value after 120 minutes) was also observed. The antioxidative activity of the extracts in the experimental systems was
compared with that of reference substances: luteolin, quercetin, BHA, BHT and sylimarin (the main agent of the well-known milk this-
tle – Silybum marianum L.).
Results of this study suggest that Helichrysum plicatum represent a natural source with antioxidant potential.
Key words: Helichrysum plicatum, flavonoids, DPPH, hydroxyl radicals, lipid peroxidation.
Tatjana Kadifkova Panovska and Svetlana Kulevanova
2001. Voucher specimens were deposited at the Herbarium
of the Institute of Pharmacognosy, Faculty of Pharmacy,
Skopje, Macedonia.
Reagents 
The reagents used were of highest purity (>99.95 purity)
and were purchased from Sigma Chemical Co (Germany).
Authentic samples of luteolin, quercetin, sylimarin, BHA
(butylated hydroxyanisole) and BHT (butylated hydroxy-
toluene) were the products of Extrasynthese (France).
Preparation of plant extracts
Dried powdered plant material (flowers, stems and
leaves separately) was cut into small pieces and extracted
in the ratio 1:10 (w/v) by three procedures: a. with metha-
nol (M-extract); b. with ethanol-water (7:3), then evapora-
ted until water remains and extracted with ethyl acetate
(EA-extract); c. hydrolysis with HCl, aglycones extracted
with ethyl acetate (H-extract). All extracts were dried over
anhydrous sodium sulfate, filtered and concentrated under
vacuum up to concentration of 1 g per 1 mL of extract. M-
extract was further diluted with methanol; EA and H
extracts with ethyl acetate, in order to obtained 0.01 g mL-1
solutions used in the experiments.
Free radical scavenging activity in 1,1-diphenyl-2-picryl-
hydrazyl radical (DPPH) assay
The antioxidant activity using the DPPH assay was
assessed by the method of Brand-Williams et al. (9). A test
sample solution (200 μL) was added to 4 mL of 100 mmol
L-1 ethanolic DPPH. After vortexing, the mixture was in-
cubated for 10 minutes at room temperature and the
absorbance at 517 nm was measured. The difference in
absorbance between a test sample and a control (ethanol)
was considered as activity. The activity was shown as IC50
value (50% of inhibitory concentration in mg mL-1). Lute-
olin, quercetin, BHA, BHT and sylimarin (100 μg mL-1 in
ethanol) were used as reference substances. All values are
shown as the mean of three measurements.
Evaluation of the hydroxyl radical scavenging activity
Hydroxyl radical scavenging activity was carried out by
measuring the competition between deoxyribose and the
extracts for hydroxyl radicals generated from the Fe3+/ascor-
bate/EDTA/H2O2 system. Attack of the hydroxyl radical on
deoxyribose led to TBARS (thiobarbituric acid-reactive sub-
stances) formation (10). The extracts were added to the reaction
mixture containing 2.8 mmol L-1 deoxyribose, 100 μmol L-1
FeCl3, 104 μmol L-1 EDTA, 100 μmol L-1 ascorbic acid, 
1 mmol L-1 H2O2 and 230 mmol L-1 phosphate buffer (pH 7.4),
making a final volume of 1.0 mL. One milliliter of thiobarbi-
turic acid TBA (1%) and 1.0 mL trichloroacetic acid (TCA
2.8%) were added to test the tube and incubated at 100oC for
20 min. After cooling, absorbance was measured at 532 nm
against a blank containing deoxyribose and buffer. Reactions
were carried out in triplicate. In the series of control experi-
ments, reference substances: luteolin, quercetin, BHA, BHT
and sylimarin (100 μg mL-1 in phosphate buffer-pH 7.4) were
used instead of the extract solution. The reaction mixture was
incubated at 37oC for 1 h.
Evaluation of antioxidant activity
The antioxidant activity of the extracts was evaluated
using a β-carotene/linoleate model system (11). A solu-
tion of β-carotene was prepared by dissolving 2.0 mg of
β-carotene in 10 mL of chloroform. One milliliter of this
solution was then pipette into a round-bottom flask. After
chloroform was rotary evaporated at 40 oC under vacuum,
20 mg of purified linoleic acid, 200 mg of Tween 40 emul-
sifier and 50 mL of distilled water were added to the flask
with vigorous shaking. Aliquots (5 mL) of this emulsion
were transferred into a series of tubes containing 2 mg of
each extract or 2 mg of BHA (butylated hydroxyanisole)
for comparison. An aliquot (5 mL) of emulsion without
any further additions was used as control. As soon as the
emulsion was added to each tube, the zero time absorbance
was read at 470 nm. Subsequent absorbance readings were
recorded at 10-min intervals by keeping the sample in a
water bath at 50 oC until the visual color of β-carotene in the
control sample had disappeared (about 120 min).
Results and discussion
Interest in the search for new natural antioxidants has
grown dramatically over the past years because reactive oxy-
gen species production and oxidative stress have been shown
to be linked to ageing related illnesses (12). Also the restric-
tions to use of synthetic antioxidants, such as butylated hydro-
xyanisole (BHA) and butylated hydroxytoluene (BHT), due
to their toxicity (13) has been an important incentive for such
research. Numerous plants have been examined for antioxi-
dant activity. According to this, antioxidant properties of
Origanum spp. (aerial parts) have been studied relatively
well over the past years (14,15,16). Also, Urtica sp., has been
shown to have antioxidant activity (17). On the other hand,
Helichrysum species have not been investigated systemati-
cally for their potential health-benefiting properties.
Free radical scavenging activity
This method is based on the reduction of DPPH, a sta-
ble free radical. Because of the odd electron of DPPH, it
gives a strong absorption maximum at 517 nm by visible
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spectroscopy (purple color). As the odd electron of the
radical becomes paired off in the presence of a hydrogen
donor, that is, a free radical scavenging antioxidant, the
absorption strength is decreased, and the resulting discol-
oration is stehiometric with respect to the number of elec-
trons captures (18). This reaction has been widely used to
test the ability of compounds to act as free-radical scaven-
gers of hydrogen donors and to evaluate the antioxidant
activity of food and plant extracts (19-21).
Free radical scavenging activity (FRSA) of Helichrysum
extracts was determined by comparing with activities of
substances such as luteolin, quercetin, BHA, BHT and
sylimarin (reference substances), which possess some
antioxidant potential. In Table 1. FRSA values obtained for
plant extracts together with reference substances in DPPH
assay are shown. Various extracts showed different activity
in this assay. Methanol extract derived from stems and
leaves showed the highest inhibitory activity with IC50 of
6 mg mL-1. The lowest DPPH scavenging activity was shown
by ethyl acetate extract derived from flowers (IC50 11 mg mL-1).
The other Helichrysum extracts demonstrated similar DPPH
scavenging activity (8-9 mg mL-1). When compared to the
reference substances, the Helichrysum extracts were found
to be less efficient in radical scavenging. Luteolin, querce-
tin, BHA, and sylimarin interacted intensively with DPPH
(IC50: 0.09, 0.06, 0.152 and 1.96 mg mL-1, respectively) while
BHT possessed moderate scavenging properties (3.52 mg
mL-1). The scavenging effects can probably be attributed
to the flavonoids present in the examined extracts, but could
also be the result of the activity of other secondary meta-
bolites, such as volatile oils, carotenoids, and vitamins,
that in the case may contributed to the antioxidant capaci-
ty (16,17).
Hydroxyl radical scavenging activity
The Fenton reaction describes the oxidation of H2O2
by Fe2+ to OH• and Fe3+. In the model employed in this ex-
periment, the production of OH• induced oxidation of the
deoxyribose, which in turn reacted with TBA to produce a
TBA reactive chromofore that was detectable at 535 nm,
thus enabling assessment of antioxidant activity of plant
extracts (10).
Fig. 1 presents the results of the effects of examined
Helichrysum extracts, reference substances (luteolin,
quercetin, BHA, BHT and sylimarin) as well as control
solution on OH• radical production. The results show that
all extracts of Helichrysum plicatum inhibited the produc-
tion of OH• radicals. The strongest inhibitory activity was
exhibited by the H-extract derived from stems and leaves
(58%). When compared to the reference substances, lute-
olin, quercetin, BHA, BHT and sylimarin (48%, 42%, 52%,
47% and 43%, respectively), the extracts had slightly lower
activity, except of H-extract derived from stems and lea-
ves with greater activity than BHT.
The findings demonstrate hydroxyl radical scavenging
potential of Helichrysum extracts against Fenton reaction
induced OH• generation, showing similar performance with
luteolin, quercetin, BHA, BHT and sylimarin. This activity
is mainly due to the redox properties of flavonoids, which
Table 1. DPPH radical scavenging activity of the 
Helichrysum plicatum extracts against luteolin, 
quercetin, BHA, BHT and sylimarin as standards.
a IC 50 denotes the extract concentration at which the absorbance shows 50 % of controlb All values are shown as the mean ± SD of more than 3 measurements
 IC50a (mg ml-1) 
Flower  extracts  
Methanol 9 ± 0.7b 
Etanol:water  11 ± 2.2 
After hydrolysis  8 ± 1.9 
Stem and leaf extracts   
Methanol 6 ± 3.0 
Etanol:water  8 ± 0.5 
After hydrolysis  8 ± 2.4 
Reference substances   
Luteolin  0.09 ± 0.01 
Quercetin 0.06 ± 0.02 
Sylimarin 1.96 ± 0.03 
BHA 0.152 ± 0.002 
BHT 3.52 ± 0.02 Fig. 1. Effects of Helichrysum plicatum extracts against 
luteolin, quercetin, BHA, BHT, sylimarin as standards 
and control on the in vitro OH• production.  
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allow them to act as reducing agents, hydrogen donors, and
singlet oxygen quenchers. They may also have a metal
chelating potential (22). The slight quantitative differences
in the amounts of flavonoids (2) might also explain the
minor differences between the activities of the extracts.
Antioxidant activity
For the screening of antioxidant potential of Helichrysum
extracts, β-carotene/linoleate model system has been applied
(11). This test involves a reaction between a potential antioxi-
dant, β-carotene and linoleic acid. β-Carotene undergoes
rapid discoloration in the absence of an antioxidant. The
presence of antioxidant compounds can hinter the extent of 
β-carotene destruction by neutralizing the linoleate free radical
and any other free radicals formed within the system.
The antioxidant activity of each extract of Helichrysum
plicatum, BHA and control is presented in Fig. 2. According
to the preventive activity against bleaching of β-carotene,
M-extract (46%) derived from flowers and H-extract
(44%) from stems and leaves are the most promising
Helichrysum extracts. M-extract (22%) and EA-extract
(29%) derived from stems and leaves showed short and
weak inhibition of bleaching, close to that of flowers EA-
extract (24%). H-extract (15%) from flowers was found to
be less efficient in this model system. The inhibitory effect
on β-carotene bleaching of the all Helichrysum extracts
was lower than that of BHA.
The antioxidant activity of Helichrysum plicatum extracts
has been attributed to various mechanisms, among which
is neutralizing β-carotene destruction. Also, we can suggest
that there is always no linear correlation between antioxi-
dant activity and the content of flavonoids (2). This indica-
tes that the concentration of flavonoids is not the only fac-
tor related to the antioxidant activity. Possible synergism
of flavonoids with other components present in the extracts
may be responsible for this observation.
Conclusion
Results of this study suggested that Helichrysum pli-
catum DC. could be regarded as a good source for natural
antioxidant. Its extracts exhibit potent free radical scav-
enging, hydroxyl radical scavenging and antioxidant acti-
vity in vitro. The information from this study can explain
the traditional use and the further development of these
extracts into new pharmaceuticals.
The data reported here can be consider as the first in-
formation on the antioxidant properties of Macedonian
Helichrysum plicatum.  Further studies are needed to eval-
uate the in vivo potential of these extracts in animal models.
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Rezime
Antioksidativen potencijal na Helichrysum plicatum DC. (Asteraceae)
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Klu~ni zborovi: Helichrysum plicatum, flavonoidi, DPPH, hidroksil radikal, lipidna peroksidacija.
Opi{ana e sposobnosta na razli~ni ekstrakti od cvetovi, stebla i listovi na H. plicatum da deluvaat kako prirod-
ni antioksidansi vo razli~ni in vitro eksperimentalni modeli vo koi se vklu~eni reakcii so slobodni radikali: inhi-
bicija na DPPH (1,1-diphenyl-2-picrylhydrazyl) radikalot, inhibicija na hidroksil radikali i za{tita na β-karoten-
linolenska kiselina model sistemot. Ispituvanite ekstrakti poka`uvaat aktivnost za fa}awe na slobodni radikali
so IC50 od 6 do 11 mg/ml. Ekstraktite se sposobni da reagiraaat so OH• radikalot so inhibicija na produkcija me|u 33-
58%. Izrazena preventivna aktivost poka`uvaat i kon promenite na β-karotenot (15-40% od po~etnata vrednost, posle
120 minuti). Antioksidativnata aktivnost na ekstraktite vo eksperimentalnite sistemi e sporeduvana so referent-
nite supstancii: luteolin, kvercetin, BHA, BHT i silimarin (glavniot aktiven princip na rastenieto mle~en trn -
Silybum marianum L.). Rezultatite od ispituvaweto uka`uvaat deka Helichrysum plicatum pretstavuva priroden izvor so
antioksidativen potencijal.
Introduction
Cystatin C (Cys C) is a nonglycosylated basic protein
(13.36 kDa) and can be found in a variety of biologic flu-
ids (1). CysC serum concentration is not influenced by
gender, inflammation, or lean tissue mass and is regarded
to be mainly determined by glomerular filtration rate
(GFR) (2, 3). Cystatin C has been described as meeting many
of the characteristics of an ideal GFR marker (e.g., endo-
genously produced at a constant rate, freely filtered in the
glomerulus, neither reabsorbed nor secreted in the renal
tubule, not extrarenally eliminated) and has been reported
to be at least as accurate as the commonly used serum cre-
atinine to detect impaired renal function in various patient
groups, including renal transplant patients (4-11).
In recent literature, cystatin C has been advocated as a
new and more accurate estimate of GFR (1).Cystatin C is
a 13-kDa endogenous cysteine proteinase inhibitor pro-
duced by all nucleated cells at a constant rate and broken
down completely in the renal tubuli (12). Cystatin C con-
centrations are independent of age and body weight, and
there is no need for urine collection for clearance estima-
tions. Furthermore, serum concentrations of cystatin C are
not influenced by malignancy or inflammation. In con-
trast, the often-used serum creatinine concentration is sup-
posedly influenced by dietary intake, renal tubular metab-
olism, age, and variations in muscle mass. There are also
various analytical difficulties with the widely used Jaffe
colorimetric assay for creatinine. A slight decrease in GFR
has been found in patients with hypothyroidism, which
improved significantly after treatment (2,3). We wondered
whether cystatin C would also be a good marker of renal
function in case of thyroid dysfunction. Thyroid hormones
have metabolic effects and thus, thyroid state could influ-
ence plasma cystatin C concentrations.
Macedonian pharmaceutical bulletin, 51, (1,2) 35-40 (2005)




Despite recent studies showing that serum Cystatin C(CysC) is a better marker for glomerular filtration rate (GFR) than the ubiqui-
tously used creatinine, the clinical utility of this remains to be evaluated. This marker is very sensitive for alograft function after renal
transplantation. Concentration of CysC was compared with that of creatinine. Decreased renal function was followed in 64 transplanted
patients. Plasma CysC significantly correlated (r=0.625, p<0.001) with creatinine in healthy controls. In these  patients the mean plasma
creatinine and Cystatin C concentrations were: 81+/-13 mmol/L,0.90 +/-0.22 mg/L, respectively. Plasma Cystatin C and creatinine signi-
ficantly correlated throughout the post-transplantation period (r=0.686, p<0.001), but we confirmed  differences between  kinetics of
these parameters. In the first four days after transplantation the CysC concentration was normalized faster than creatinine concentration.
Development of acute rejection episode ( between 5 and 7 days) showed high sensitivity and specificity of the changes of CysC com-
pared with those of creatinine.
Key words: renal transplantation, delayed graft function, cystatin C
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Patients are at risk of acute damage of the transplanted
kidney because of rejection or toxicity from immunosup-
pressant therapy. Earlier detection of renal damage may
lead to more effective intervention. In a preliminary study,
LeBricon et al. (13) first suggested that CysC was more
sensitive than serum creatinine(SCr) for detecting decreas-
es in GFR and delayed graft function in renal transplant
patients. As in most studies, plasma CysC measurements
correlated well with SCr and creatinine clearence (CrCl).
However, in the three cases of acute renal rejection that
were confirmed by biopsy, the increase in plasma CysC
values was more pronounced than that observed for SCr.
After renal transplantation, plasma (or serum) creati-
nine is the most common marker for assessment of allo-
graft function. In a steady-state muscular mass balance,
the plasma creatinine concentration is assumed to reflect
glomerular filtration rate (GFR) (14). However, plasma
creatinine is far from being an ideal marker of GFR, des-
pite its convenience and low cost (15) Plasma creatinine
suffers a high degree of interindividual variability related
to sex, age, body composition, and dietary factors (16).
With altered renal function, the plasma creatinine concen-
tration increases only when the GFR is reduced by >50%.
Furthermore, secretion or reabsorption of creatinine by the
renal tubule is highly unpredictable, thus leading to under-
or overestimation of GFR (15).
Numerous drugs and endogenous substances also
interfere with the measurement of creatinine by the Jaffé
technique or enzymatic methods, leading to falsely high
or low creatinine values (17).
Experimental
Samples
Sixty-four patients with end-stage renal disease
undergoing renal transplantation were included in this
study. Primary diagnosis of the investigated patients was:
chronic interstitial nephropathy (n = 8), diabetic glomeru-
lopathy (n = 12), polycystic kidney disease (n = 3),
nephrosclerosis (n = 3), focal segmental glomerulosclerosis
(n = 10), IgA nephropathy (n = 8), membranous glomeru-
lonephritis (n = 11), mesangiocapillary glomerulonephri-
tis (n = 1), and unknown (n = 4). Immunosuppressive regi-
men included steroids (methylprednisolone at the initial
dose of 500 mg, followed by 1 mg · kg-1 · day-1, progressi-
vely tapered) and cyclosporine A (initial dose of 8 mg ·
kg-1 · day-1, and then adjusted according to blood concentra-
tions) or FK506 in cases of cyclosporine intolerance (at
the dose of 0.1 mg · kg-1 · day-1). The patients were classi-
fied indo two groups according to the clinical diagnosis:
with or without delayed graft function.
The control group consisted of 50 healthy persons.
They were free of cardiac, liver or renal diseases or hyper-
tension and had normal urine analysis and normal sera
urea,creatinine and Cys C concentration.
Methods
Delayed graft function (DGF) was defined as a require-
ment for dialysis during the first 2 weeks after transplanta-
tion. All patients were on conventional dialysis. Episodes
of acute rejection diagnosed by renal biopsy were treated
with 5 days of intravenous methylprednisolone. This study
was in accordance with the ethics standards of the Helsinki
Declaration of 1975, revised in 1983.
Allograft function was evaluated on a daily basis
starting on the day of surgery (day 0) and for 25 days the-
reafter or until hospital discharge, whichever occurred
first. Blood (7 mL) was drawn by venipuncture in a
Vacutainer® Tube (Becton Dickinson) before centrifuga-
tion (3500g at 20 °C for 15 min) and analyzed for creati-
nine and CysC. Creatinine concentration was enzymati-
cally assayed on a INTEGRA biochemical analyzer. The
sample volume was 10 µL, and the assay was performed at
37°C; total analysis time was 7 min. The interassay impre-
cision (CV; n = 50) was <3%.
The concentration of CysC was measured using a
DAKO Immunoturbidimetric assay on a Cobas Mira bioche-
mical analyser.The reference  serum interval was 0.80 –
1.25 mg/L. Briefly, the assay is performed at room tempera-
ture with a six-point calibration covering the range of
0.23–7.25 mg/L. The calibrator used is a purified Cys C
from human urine (1.45 mg/L). The sample volume is 80 µL.
The time for analysis is 6 min, each subsequent sample reading
being available after 8 s. The interassay CV (n = 20) was <4%
for both the low (1.4 mg/L) and high (4.2 mg/L) controls.
Calculations
The percentage of discordant changes in plasma
cystatin C and creatinine concentrations was calculated
on a day-to-day basis after transplantation. A change in
opposite direction (increase/decrease) of >10% between
the two markers was considered as discordant. On hospi-
tal discharge or at the end of the 25 days period, creati-
nine clearance was estimated from plasma creatinine
using the formula of Cockcroft and Gault (14). A cutoff
of 80 mL/min was selected for normal estimated creati-
nine clearance (25).
Statistical analysis
Data are presented as mean ± SD or as median and
range when appropriate after checking for gaussian distri-
bution. Differences between two groups were evaluated
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by the Wilcoxon’s signed-rank test. Multiple comparisons
were performed by the Friedman’s repeated-measure
ANOVA on ranks followed by the Dunn’s test. Correlation
between techniques was evaluated by linear regression
and ANOVA. Results with P <0.05 were considered statis-
tically significant.
Results and discussion
CysC and creatinine concentration were measured in
50 healthy adults (39 +/- 9 years). Data were analyzed by
linear regression and ANOVA (P < 0.05 considered signif-
icant).The concentration of Cystatin C significantly corre-
lated (r = 0.625; P<0.001) with creatinine ( Fig. 1). Cysta-
tin C serum concentration was not influenced by age
(r=0.195; not significant). The calculated reference inter-
val for creatinine was  58-109 mmol/L (males and  females)
and the cystatin C : 0.80 – 1.25 mg/L.
Transplant patients were separated into two groups:
normal course (absent of complications; n= 38) (Fig. 2);
DGF and acute rejection episode defined as requiring hemo-
dialysis during the first 2 weeks after surgery (n=26).  
In patients without DGF a significant decline in plasma
concentration was more rapidly obtained for cystatin C
that for creatinine.
Starting on day 4 post-transplantation the decrease in
plasma concentration in patients without DGF was more
pronounced for creatinine that for cystatin C (Fig. 3).
In patients with DGF, the reduction in plasma concen-
tration was not significant until  day 14 for creatnine and
day 17 for cystatin C.
At the end of the 25 days - study period, a 50% reduc-
tion from the initial plasma creatinine concentration was
observed in patients with DGF vs 35% for Cystatin C.The
frequency of discordant daily changes in cystatin C and
creatinine values was significantly higher in patients with
DGF(40%) than in those without DGF (21%,P < 0.01).
In cases with acute rejection episode was demonstrat-
ed by persistent increases in both plasma creatinine and
cystatin C concentration. Serum cystatin C gradually
increase (115%) during 7 days before diagnosis (nephro-
toxicity – FK506-regressed spontaneously).
At the end of the study (day 25), serum creatinine was
150 µmol/L (79–602 µmol/L) vs 2.12 mg/L (1.04–5.54 mg/L)
for cystatin C. Both markers significantly correlated 
(r = 0.812; P <0.001). Estimated creatinine clearance by
the Cockcroft and Gault formula (14) in patients with sta-
ble renal function (no hemodialysis during the last week,
n = 19) was 49 mL/min (15–66 mL/min), and no patient
was within the reference interval (>80 mL/min). Serum
creatinine was within the reference interval for three
patients (80-109 µmol/L) compared with none for cystatin C.
The relationship between estimated creatinine clearance
and the serum concentrations of creatinine and cystatin C
in patients with stable renal function (n = 22) is presented
in Fig. 4 and 5.
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Fig. 1. Relationship between serum Cystatin C and serum 
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Fig. 2. Serum Cystatin C and serum creatinine in renal 
transplant patients without DGF
Todor Gruev, Margarita Boncheva, Olivera Stojceva-Taneva, Angel Mitrevski, Vasko Aleksovski
There was a significant correlation between estimated
creatinine clearance and serum cystatin C (r = 0.714; P <0.001).
Discusion
Sensitive and reliable recognition of changes in GFR is of
primary importance in transplant patients. A DGF is an
identified and independent risk factor for graft survival
(26) Acute rejection is also an established risk factor for
renal graft failure, defined as a return of patient to hemo-
dialysis (18-20). Recent studies have suggested that cysta-
tin C might be a potential better marker of GFR than plas-
ma creatinine such as in renal transplant patients (28-30).
The mean cystatin C plasma concentration in our group
of healthy adults was similar to that reported in a group of
healthy subjects (n = 50; mean age, 40 years), using an
immunoturbidimetric assay (0.65 ± 0.05 mg/L) (30). Slightly
higher values (mean cystatin C, 0.80 mg/L) were reported
by others (27) in a group of 52 adults with normal renal
function (ages, 21–79 years). These data are in agreement
with an increase in plasma cystatin C values with age,
especially after the age of 50 years (35). We found no the
sex difference reported previously (22,23). Serum cystatin
C correlated poorly with serum creatinine, as reported pre-
viously in subjects with GFR >80 mL/min (24) or GFR >70
mL · min-1 · 1.73 m-2 (23). These data suggest that different
physiological factors (such as sex, dietary factors, or body
composition) influence cystatin C and creatinine plasma
concentrations in healthy adults.
In renal transplant patients, plasma cystatin C concen-
trations paralleled those of creatinine regardless of graft
function  (absence or presence of DGF). Consequently,
serum cystatin C and creatinine significantly correlated
over the postoperative study period as observed previous-
ly in adult renal transplant patients (31) and subjects suf-
fering from chronic renal disease (13). Some differences,
however, were apparent in their respective plasma kinet-
ics. During the first 4 days post-transplantation, the cys-
tatin C serum concentration decreased more rapidly than
that of creatinine. Tanstubular leakage of the low-molecu-
lar weight (Mr 100) creatinine (23) has been reported in
acute renal failure, thus leading to high plasma creatinine
values. Starting on day 4 post-transplantation, decrease in
serum concentration became more prominent for creati-
nine than for cystatin C, which might be attributable to an
underestimation of GFR by plasma cystatin C, an overes-
timation of GFR by plasma creatinine, or both. A stronger
correlation between cystatin C than between creatinine
and the measured GFR has been reported in adults suffer-
ing from renal diseases (18).
For patient follow-up, the ability to detect rapid changes
in GFR is clinically more important than accuracy itself.
With diminished GFR, a significant increase in plasma
concentration of cystatin C and creatinine will depend on the
rate of its accumulation in plasma, which depends on its
production rate and distribution volume, but also on its
biological intraindividual variation. Repeated measures
obtained in healthy subjects (30) suggested that intrain-
dividual variation might be more important for cystatin C
(13.3%) than for creatinine (4.9%). If true, cystatin C
would be less sensitive for the detection of acute rejection
episodes for a given individual than creatinine (30). In all
episodes of acute rejection and acute nephrotoxicity in our
study, the plasma cystatin C concentration broadly paral-
leled that of creatinine.  The rise in plasma cystatin C con-
centration was more prominent than in creatinine. 
After renal transplantation, hemodialysis was required
in almost 55% of our patients. We found a higher degree of
discrepancy (45% of discordant results; P <0.01) between
cystatin C and creatinine kinetics in patients requiring hemo-
dialysis than in those with a normal course (19%). In addi-
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Fig. 5. Relationship between serum creatinine and GFR
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tion, cystatin C and creatinine weakly correlated in hemodi-
alyzed patients (r = 0.429). The molecular weight of cys-
tatin C is 13 300 with an Einstein-Stokes radius of 30–40 Å,
which is much higher than creatinine (Mr 100 and 3 Å) (15).
In a large study of 112 patients on stable maintenance
hemodialysis, a 30% reduction in serum cystatin C was
observed after dialysis with mostly AN69 high-flux mem-
branes (23). As expected, the elimination of cystatin C dur-
ing dialysis increased with the ultrafiltration coefficient
(UFC) of the membrane, an estimate of the permeability:
0% (vs 40% for creatinine) for UFC <15 mL · h-1 · m2 · mmHg
and ~ 60% (as for creatinine) for UFC >15 mL· h-1 · m2 · mmHg
(23). Thus, removal of cystatin C by hemodialysis seems
highly dependent on the type of membrane selected. This is
an important issue in renal transplantation because it could
limit the use of plasma cystatin C as a marker of graft func-
tion in patients with DGF. On the other hand, if poorly fil-
tered by dialysis membranes, plasma cystatin C could be
used by the nephrologist to monitor appropriate duration of
hemodialysis in patients with DGF. Prolonged unnecessary
hemodialysis could be avoided as soon as a significant de-
crease in plasma cystatin C is obtained by dialysis.
In conclusion, the determination of cystatin C concen-
tration is an alternative and more accurate marker of GFR
than creatinine in adult transplantation. In some cases, a
more prominent rise in serum cystatin C values allows a more
rapid diagnosis of acute rejection or treatment nephrotoxicity.
Further prospective studies are needed to evaluate this last
issue and the potential of plasma cystatin C in the long term
follow-up of graft function in renal transplantation.
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Serum Cistatin C kaj pacienti so naru{ena graft funkcija
Todor Gruev1, Margarita Bon~eva2, Olivera Stoj~eva - Taneva3,
Angel Mitrevski1, Vasko Aleksovski1
1Institut za klini~ka biohemija, 3Klinika za nefrologija, 
Univerzitetski klini~ki centar, Skopje, Makedonija,
2Univerzitetska klinika „Lozenec“, Sofija, Bugarija
Klu~ni zborovi: renalna transplantacija, naru{ena graft funkcija, Cystatin C
Izrabotenata  studija uka`uva deka serumskata koncentracija na Cystatin C (Cys C) e podobar marker za GFR vo
sporedba so standardniot kreatinin, {to be{e i klini~ki evaliurano. Ovoj marker e mnogu poosetliv za graft
funkcijata posle bubre`na transplanatacija. Koncentracijata na Cys C e sporedena so onaa na kreatininot. Nama-
luvaweto na bubre`nata funkcija e sledeno kaj 64  transplantirani pacienti. Koncentracijata na Cys C signifi-
kantno korelira (r=0.625, p<0.001) so kreatininot kaj kontrolnata grupa. Kaj ovie pacienti srednite kreatinin i
cistatin C koncentracii se: 81+/-13 mmol/L odnosno 0.90 +/-0.22 mg/L. Plazma koncentraciite na cistatin C i kreati-
ninot signifikantno koreliraat vo post-transplantacioniot period (r=0.686, p<0.001), no potvrdivme razliki vo
kinetikata na ovie parametri. Vo prvite ~etiri dena posle transplanatacija Cys C se normalizira pobrzo od taa
na kreatininot. Razvitokot na akutna reakcija (pome|u 5 i 7 den) uka`uva na visokata osetlivost i specifi~nost
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Cold pressed orange oil is widely used in beverage,
perfumery industry and aromatherapy. In general, there are
two types of orange oils: sweet orange oil from Citrus sinensis
and bitter orange oil from Citrus aurantium.
Sweet orange oil is the most widely used citrus oil. It
possesses a light sweet, fresh top note with fruity and alde-
hydic character (1). It is widely used in the flavour indus-
try especially in beverages and candies. It can provide the
top note for citrus flavouring as well as characteristic and
most universally accepted flavour. The sweetness and in
the same time the refreshing note makes them appropriate
base for still and carbonated soft drinks.
Most of the orange oils on the world market are Italian
and American industrial oils, but there are also oils produced
in Spain, and in the South American countries. Moreover,
studies on laboratory-extracted oils from the peel of fruits of
special cultivars from different regions such as Algeria, Li-
bya, Israel, Russia, China and Japan have been published (1).
Bitter orange oil possesses fresh citrus top notes, but
is considered less sweet, and even bitter and dry. It has flo-
ral and aldehydic characteristics (1). The tenacity is greater
than the most other citrus oils. In flavourings, this oil can
be used to provide a citrus top note or act as a modifier in
the citrus blend. The major application is in the citrus flavourings
for beverages, especially liqueurs. It also intensifies the
orange character in soft drinks.
Most of the papers pertinent to sweet orange oil com-
position were reviewed by Sawamura (2, 3) and Lawrence
(4). A large number of papers deal with the composition of
the volatile fraction of sweet orange oil and in many of
them its differences in relation to the cultivars are reported
with particular references to the different content of
aliphatic aldehydes and linalool (5-10), and the volatile
components of bitter orange oil (11,12).
The goal of this work is to present a way of compara-
tive investigation of the cold pressed sweet and bitter
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Abstract
The volatile fraction composition of commercially produced sweet and bitter orange oil from fruit peels was studied using GC-MS.
More than fifty components were identified in the oils using their mass spectra and linear retention indices. The monoterpene limonene
was the most abundant component even though not in a quantity expected for a fresh orange essential oil. Aldehydes, followed by alco-
hols and esters, were the main components in the oxygenated fraction. Aldehydes were the major oxygenated components in the sweet
orange oil, whereas alcohols and esters were present in higher amounts in the bitter orange oil. Among them, nonanal, decanal and
linalool are the most important components for the flavour of sweet orange oil and carvon is the most important ketone for the flavour
of bitter orange oil in combination with the other components. The amount of carvon gives a good indication about the freshness of the
oil and the quantities of α-pinene and β-pinene, sabinene and myrcene give an indication about the natural or artificially changed com-
position of the essential oils. 
Key words: Citrus sinensis, Citrus aurantium, peel oil, GC-MS, volatile components
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orange oils found in the market and to see the difference
between the oils. The results are compared with the pub-
lished ones for fresh orange oils and some indications about
the freshness and the origin are discussed.
Experimental
Two commercial samples of oils produced from peel
of Citrus sinensis and Citrus aurantium were kindly sup-
plied from an Italian flavour company.
Each sample was analysed by GC/MS using a HP
6890 Gas chromatograph equipped with a HP 5973 mass
selective detector with a HP-5 fused silica column 
(30 m x 0.25mm, 0.25 μm film thickness). The column tem-
perature was changed linearly from 40 to 180 ºC by 4 ºC/min,
and after that 20ºC/min to 260ºC. 0.2 μL were injected at a
split ratio of 1:100. The inlet temperature was 260ºC and the
transfer line temperature was 280ºC.
The MS library used was Wiley 275. Also, compound
identification was checked by linear retention indices with
standard series of alkanes (C8-C32) and compared with the
LRI values in the database of the Citrus Research and
Education Centre at the University of Florida (13) and in
the book of Adams (14).
Results and discussion
Sample preparation is one of the most important proces-
ses in flavour research, because the aroma compounds are
substantially volatile and unstable against heat (3). GC-MS
is a valuable tool in characterization of essential oils because
the interpretation of the results of qualitative and quantita-
tive analysis can enable an insight in the process of produc-
tion, storage and age of the commercially produced oils.
In this work, more than fifty components were identi-
fied in the analysed sweet and bitter orange oils. The iden-
tified compounds and their linear retention indices calcu-
lated on HP-5 column are given in Table 1. For each sam-
ple, the quantitative composition (as a relative percentage
of peak area) for each component is given together with
the aroma descriptors for the components as found in the
database of the Citrus Research and Education Centre at
the University of Florida (13) and by Choi (15).
The GC-MS chromatograms obtained for both sam-
ples of essential oils of sweet and bitter orange oil are giv-
en in Fig. 1 and Fig. 2, respectively.
The data in Table 1 show that different quantities and
ratios of the same components give different taste of the
aroma. According to the data, the quantities of α-pinene,
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Fig. 1. Chromatogram of sweet orange peel oil
camphene, myrcene and octanal are higher than the usual
values for cold-pressed sweet and bitter orange oil (1). On
the other hand, the quantities of limonene are lower (76.65
% in sweet orange oil and 71.2 % in bitter orange oil) than
expected according to the published data for fresh sweet
and bitter orange essential oils (over 90 %) (1).
The quantity of α-terpinolene which gives the citrus and
pine note according to odor description database of Citrus
Research and Education Centre (13) is almost six times
greater in bitter orange oil than in sweet orange oil. The quanti-
ty of valencene in sweet orange oil is more than double com-
pared to bitter orange oil, which is expected because this com-
pound gives the specific sweet citrus odor for sweet orange.
Aldehydes are the most important compounds for the
citrus flavour. The quantity of aldehydes in sweet orange
peel oil is double compared to the aldehydes content in the
bitter orange oil. Octanal, nonanal and decanal, which are
very active odor compounds and have a sweet note, are in
higher quantity in sweet than in bitter orange oil (2). 
On the other hand, alcohols content in bitter orange
oil is higher than in sweet orange oil, but linaool in both
analysed commercial oils is in bigger quantity than
expected from the published data (1).
Also the quantity of esters is three times higher in bit-
ter orange oil in comparison to quantity of esters in sweet
orange oil, because the quantity of geranyl acetate and
linalyl acetate are very high in bitter orange oil. 
There are some components expected and identified
in the in bitter orange oil like +-2-carene, n-octyl acetate,
linalyl acetate, 2,4-decadienal, δ-elemene, germacren B,
nerolidol, bergapten, which are missed in the sweet orange
oil. β-pinene is also missed in sweet orange oil and it is
present in bitter orange oil in enough high quantity.
It is well known that the bitter taste of bitter orange oil
predominantly comes from the nonvolatile components of
the peel, but also the volatile components give a signifi-
cant part of the aroma of bitter orange oil (1). The compo-
nent which gives a bitter odor, carvon, is in higher quanti-
ty in bitter orange than in sweet orange oil. It has been
observed that orange oil deteriorates very rapidly in aque-
ous acidic environment and under the influence of light
and oxygen. Relatively high quantity of carvon in both
oils has been identified as the major degradation product
(Fig. 3), and has also been reported as a constituent of var-
ious old citrus oils (11, 16). From this we can include that
the oils purchased from the market are not fresh.
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Fig. 2. Chromatogram of bitter orange peel oil
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All these results indicate that the two commercially
produced orange oils purchased from the flavour market are
not fresh and original cold pressed essential oils, but some
of the components, like limonene, are removed from the oil
and some of the components, like α-pinene, sabinene are
added to the oils by physical or chemical methods (1).
In conclusion, the qualitative and quantitative analysis
of the commercial bitter orange oil shows that this oil is not
pure cold pressed oil because the ratio α-pinene/β-pinene
is greater then 0.8 which indicates addition of grapefruit
terpenes in the bitter orange oil (1). On the other hand, the
significant amount of myrcene (>2 %) and octanal (>0.2
%) in the commercial sweet orange oil gives an indication
that the oil is not an original cold pressed oil, but has been
modified in the manufacturing process, which is also sup-
ported by the significantly reduced content of limonene.
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Fig. 3. Biosynhesis of limonene and its transformation 
to carvone during storage
 Component LRI % in C. sinensis  
% in 
C. aurantium Aroma descriptor [13, 15] 
 Monoterpenes      
1. á-tuje ne 926 0.02 0.02  
2. á-pinene 932 2.57 2.10 pine-like, resinous, green, sweet  
3. camphene 947 0.01 0.06 warm, oily, camporaceous  
4. sabinene 972 1.83 0.84 warm, oily, peppery, green  
5. myrcene 992 6.90 5.86 musty, wet soil  
6. á-terpinolene 1090 0.13 0.77 citrus, pine  
7. ä-3-carene 1010 0.79 0.37 sweet 
8. limonene 1033 76.65 71.2 citrus-like, fresh 
9. trans-â-ocimene 1054 0.10 0.32 herbacous, flowery, sweet, warm  
10. â-phellandrene 1060 0.01 - citrus-like, fresh 
11. ã-terpinene 1062 0.23 0.67 lemony, lime-like 
12. â-pinene 975  0.79 resinous, dry, woody  
13. á-terpinene 1021  0.05 lemony, citrusy  
14. +-2-carene 1088  0.20  
15. ä-4-carene 1351  0.02  
 Total  89.24 83.27  
 hydrates      
16. cis-sabinene hydrate  1070 0.03 0.04  
 Total  0.03 0.04  
 alcohols      
17. octanol 1074 0.07 0.11 soapy 
18. linalool 1103 2.30 2.50 floral, green, citrus  
19. á-terpineol 1192 0.31 0.83 floral, lilac -like 
18. nerol 1233 0.07 - fruity, floral  
20. elemol 1552 0.06 0.02 sweet, woody, faint  
21. nerolidol 1566  0.12 woody, floral, mild  
 Total  2.81 3.58  
 aldehydes      
22. octanal 1004 0.96 0.67 fatty, tallowy, citrus -like 
23. nonanal 1107 0.22 0.17 piney, floral, citrusy  
24. citronellal  1155 0.25 0.12 powerful, floral, lemon  
25. decanal 1208 1.27 0.78 beefy, musty, marine, cucumber  
Table 1. Percentage composition as single components for the two different orange oils, the LRI index for each component of HP-5 
column and aroma descriptors
Comparative investigation of the sweet and bitter orange essential oil (Citrus sinensis AND Citrus aurantium)
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26. neral 1243 0.24 0.15 lemony, citrusy  
27. geranial 1273 0.42 0.27 citrus-like, flowery, fruity  
28. perillaldehyde  1276 0.14 -  
29. undecanal 1309 0.08 - pleasant waxy, floral  
30. tridecanal 1410 0.24 0.15 waxy, fresh, citrusy, powerful  
31. tetradecanal  1614 0.01 - fresh, herbaceous  
32. á-sinensal 1757 0.06 0.02 orange-like 
33. â-sinensal 1700 0.17 0.08 orange peel 
34. 2,4-decadienal 1319  0.02 geranium, powerful  
35. 3-dodecen-1-al 1468  0.04  
 Total  4.06 2.47  
 esters     
36. citronellyl acetate  1356 0.01 - fresh, rosy, fruity  
37. neryl acetate  1367 0.02 0.12 fruity, floral, very sweet  
38. geranyl acetate  1386 0.02 0.22 dry, herbaceous  
39. n-octyl acetate  1214  0.09 fruity, slightly fatty  
40. linalyl acetate 1259  2.54 floral-fruity 
 Total  0.05 2.97  
 sesquiterpenes      
41. á-copaene 1377 0.16 0.08  
42. â-cubebene 1392 0.18 0.07 fruity, green  
43 â-elemene 1394 0.07 0.06 fruity 
44. aromadendrene  1397 0.02 -  
45. ä-elemene 1339  0.05  
46. trans-â-caryophyllene  1421 0.14 0.32 citrus-like, fresh 
47. germacrene-D 1483 0.11 0.22  
48. trans-á-bergamotene 1437 0.01 0.06  
49. á-humulene 1455 0.03 0.04 woody 
50. trans-â-farnesene 1458 0.04 0.03 sweet, fruity  
51. á-amorphene 1478 0.03 0.02  
52. germacrene-B 1559 0.04 0.01  
53 â-selinene 1485 0.01 0.01  
54. valencene 1495 0.34 0.15 sweet, woody, citrusy  
55. bicyclogermacrene  1498 0.04 0.03  
56. á-muurolene 1510 0.07 -  
57. â-bisabolene 1519 0.07 0.07  
58. ä-cadinene 1526 0.19 0.09 woody, dry, mild  
      
59. bergapten -  0.12  
      
 Total  1.55 1.43  
 oxides     
60. caryophillene oxide  1585 0.04 0.03 woody, spicy 
61. cis-limonene oxide  1135 0.03 0.09 citrus like 
62. trans-limonene oxide  1140 0.07 0.09 citrus like 
 Total  0.14 0.21  
 ketones     
63. carvone 1246 0.07 0.09 bitter, spearmint, caraway  
64. nootkatone 1808 0.05 0.03 green, grapefruit  
 Total  0.13 0.12  
 acids     
65. hexadecanoic acid  1890 0.03 0.06  
 Total  0.03 0.06  
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Sporedbeno ispituvawe na eteri~ni masla 
od sladok i gor~liv portokal
Sawa Kostadinovi}1, Marina Stefova1* i Diana Nikolova
1Institut za hemija, Prirodno-matemati~ki fakultet, 
Univerzitet „Sv. Kiril i Metodij“, Skopje, Makedonija
2Institut za Organska hemija so Centar za Fitohemija, 
Bugarska Akademija na naukite, Sofija, Bugarija
Klu~ni zborovi: Citrus sinensis, Citrus aurantium, maslo od kora od portokal, GC-MS, isparlivi komponenti
Ispituvan e sostavot na isparlivata frakcija na maslo od korata na komercijalni primeroci od gor~liv i sla-
dok portokl, koristej}i ja tehnikata na gasna hromatografija so masena spektrometrija. Identifikuvani se pove}e
od 50 komponenti vo soglasnost so nivnite maseni spektri i relativni retenciski indeksi. Najzastapena komponenta
e monoterpenot limonen no ne vo koli~inite koi mo`at da bidat o~ekuvani od sve`o eteri~no maslo od portokal.
Aldehidi, a potoa alkoholi i esteri se glavnite komponenti vo oksigenirana frakcija na masloto. Vo masloto od
sladok portokal, aldehidite se dominantni oksigenirani komponenti dodeka vo masloto od gor~liv portokal alko-
holite i estrite se pronajdeni vo pogolemo koli~estvo. Najbitni komponenti za mirisot na eteri~noto maslo od sla-
dok portokal se nonanal, decanal i linalol a za masloto od gor~liviot portokal toa e ketonot karvon vo kombinaci-
ja so drugi komponenti. Koli~estvoto na karvon e indikator za sve`inata i starosta na masloto dodeka od koli~est-
vata i soodnosot na α - pinen, β - pinen, sabinen i mircen mo`e da se proceni dali ima ve{ta~ki promeni vo prirod-
niot sostav na eteri~no maslo.
Upatstvo za avtorite
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UPATSTVO ZA AVTORITE
Makedonskiot farmacevtski bilten e ofici-
jalno glasilo na Makedonskoto farmacevtsko
dru{tvo. Vo spisanieto se objavuvaat originalni
nau~ni trudovi, kusi soop{tenija, revijalni tru-
dovi i stru~ni trudovi od site farmacevtski dis-
ciplini i srodni podra~ja na rabota koi se od
interes za farmacijata (farmacevtska i medicin-
ska hemija, imunologija so imunohemija, moleku-
larna biologija, farmacevtski analizi, kontrola
na lekovi, farmacevtska tehnologija, farmakoin-
formatika, biofarmacija, farmakologija, prime-
neta botanika, farmakognozija, toksikologija,
klini~ka farmacija, hrana i ishrana, fizi~ka
farmacija, organski sintezi, socijalna farmaci-
ja, istorija na farmacija i dr.).
Vo Makedonskiot farmacevtski bilten se obja-
vuvaat i drugi prilozi (poraki i soop{tenija,
izve{tai i kalendari na nau~ni i na stru~ni mani-
festacii vo zemjata i vo stranstvo, pregledi na kni-
gi). Sostaven del na Biltenot se i razni rubriki.
Originalnite nau~ni trudovi gi sodr`at rezul-
tatite na sopstveni, dotoga{ neobjaveni nau~ni
istra`uvawa koi pretstavuvaat zaokru`ena celi-
na, a davaat pridones kon razvojot na soodvetnata
nau~na oblast. Brojot na stranicite (zaedno so sli-
kite i so tabelite) ne treba da bide pogolem od 15.
Kusite soop{tenija sodr`at rezultati od na-
~ni istra`uvawa prezentirani vo pomal obem,
~ij broj na stranici ne treba da bide pogolem od
pet (dozvoleni se edna tabela i edna slika). 
Pregledite se pi{uvaat na pokana od Uredu-
va~kiot odbor, a pretstavuvaat poop{iren pri-
kaz na istra`uvawata i soznanijata na pove}e
avtori vo opredelena nau~na oblast, za koja kom-
pentnosta na avtorot na pregledot e potvrdena
preku negovite objaveni istra`uvawa.
Stru~nite trudovi izvestuvaat za korisni re-
zultati koi ovozmo`uvaat podatocite od origi-
nalnite nau~ni istra`uvawa da bidat primeneti
vo prakti~nata rabota. Stru~nite trudovi mo`at
da se temelat i na obrabotka na teoretski podato-
ci. Brojot na stranicite (zaedno so slikite i so
tabelite) ne treba da bide pogolem od 10.
Originalnite nau~ni trudovi, kusite soop{te-
nija i pregledite treba da bidat napi{ani na
angliski jazik, dodeka stru~nite trudovi i site
ostanati prilozi mo`at da bidat napi{ani i na
makedonski jazik.
Prifa}aweto na trudovite za pe~atewe vo Bil-
tenot gi obvrzuva avtorite istite rezultati da ne
gi objavuvaat vo drugo spisanie.
Podgotovka na rakopisot:
Rakopisite treba da se dostavat vo tri prime-
roci ispe~ateni na kompjuterski pe~ata~, edno-
strano so prored od 1,5 so margina od 3,0 cm od se-
koja strana, na hartija so format A4 na adresa na
glavniot urednik: 
Prof. d-r Svetlana Kulevanova
Farmacevtski fakultet, 
Vodwanska 17, 1000 Skopje,
Republika Makedonija 
Stranicite i prilozite treba da bidat numeri-
rani.
Pri podgotvuvawe na rakopisot za pe~atewe
treba da se vodi smetka toj da bide maksimalno
koncizen, bez nepotrebni povtoruvawa.
Pri pi{uvawe na rakopisot zadol`itelna e
upotreba na slednite edinici za: dol`ina (m, cm,
mm, μm, nm, Å); masa (kg, g, mg, μg, ng, pg); volumen
(l, ml, μl); vreme (s, min, h, d); temperatura (oC, K);
radijacija (Bq, Ci, dpm, Gy, rad): koncentracija (M,
mol/l, N, mg/ml, %, %(v/v), %(w/v), ppm). 
Imiwata na supstanciite treba da se vo soglas-
nost so preporakite i pravilata dadeni od IUPAC
ili, ako takvi ne postojat, spored praktikata na
Chemical Abstracts.
Tabelite i slikite (fotografii, dijagrami i
skici), kako i strukturnite formuli treba da bi-
dat dadeni sekoja na oddelen list (vo tekstot da e
obele`ano nivnoto mesto). Tabelite i slikite se
numeriraat so arapski brojki (na pr. Tabela 1., Sl.1).
Rakopisot treba da sodr`i: naslov, apstrakt,
klu~ni zborovi, voved, eksperimentalen del, re-
zultati i diskusija, zaklu~ok, blagodarnost (po
potreba), literatura i rezime.
Na naslovnata stranica treba da stoi naslovot
na rakopisot. Vo posebni redovi treba da stoi
polno ime i prezime na avtorite, naziv i adresa
na institucijata na avtorite. Koga avtorite
poteknuvaat od pove}e razli~ni institucii tre-
ba da se ozna~i potekloto na sekoj avtor so 1, 2, 3....
na krajot od negovoto ime. So yvezdi~ka treba da
bide ozna~eno imeto na avtorot za korespodenci-
ja. Vo dolniot lev agol od naslovnata stranica se
naveduva negovata e-mail adresa, telefonskiot
broj i broj na faks. 
Upatstvo za avtorite
Apstraktot treba da bide do 250 zbora (nau~ni
i stru~ni trudovi), odnosno do 100 zbora (kusi
soop{tenija), a treba da gi sodr`i celta na rabo-
tata, metodologijata i pozna~ajnite rezultati.
Vo prodol`enie treba da bidat zastapeni tri do
{est klu~ni zbora rasporedeni spored redosle-
dot na va`nost.
Vo vovedniot del treba nakuso da se navedat samo
najva`nite podatoci od porane{nite istra`uva-
wa povrzani so obrabotuvanata problematika i
da se objasni celta i va`nosta na rabotata.
Eksperimentalniot del treba da bide izdvoen
i da sodr`i podatoci za upotrebuvanite materi-
jali i opis na primenetite metodi na na~in {to
}e ovozmo`i reproducirawe na postapkata, no
bez detalno opi{uvawe na ve}e poznatoto.
Trudovite {to se odnesuvaat na teoretski istra-
`uvawa, namesto eksperimentalen del treba da
imaat soodvetno poglavje so podnaslovi vo koe }e
bidat izneseni podrobnosti neophodni za prover-
ka na prezentiranite rezultati.
Rezultatite i diskusijata treba da bidat dade-
ni vo edno poglavje. Diskusijata treba da sodr`i
analiza na rezultatite i na zaklu~ocite {to pri-
toa mo`at da se izvle~at.
Zaklu~okot {to proizleguva od izlo`enite
rezultati i diskusija se izdvojuva vo posebno
poglavje.
Literaturata se naveduva vo posebno poglavje,
pri {to bibliografskite edinici se numeriraat
po onoj red po koj se pojavuvaat vo tekstot. Ako vo
tekstot se spomnuvaat avtori, se naveduvaat samo
prezimiwata na avtorite (ako gi ima eden ili dva),
a vo slu~aj na pove}e avtori se pi{uva, na primer,
Vetter et al. (1).
Statii od nau~ni spisanija se citiraat na ovoj
na~in:
1. P. Premov and D. Dulanov, Maced. Pharm. Bull., 20,
2-10 (2000).
Kratenkite na spisanijata se naveduvaat spo-
red Chemical Abstracts.
Knigi se citiraat na ovoj na~in:
2. A. Robert, M. Sporn, Progress in Organic Chemistry,
3rd ed., Butterworths Scientific Publications, London,
1998, pp 125-154.
Knigi so urednik:
3. J. Cook, in The retinoids, P. Cornwell, Ed., Academic
Press, Orlando, 1996, pp 25-29.
Trudovite napi{ani na angliski jazik na kra-
jot treba da sodr`at rezime na makedonski jazik.
Rezimeto treba da sodr`i naslov, polno ime i pre-
zime na avtorot/avtorite, naziv na institucijata
na avtorot/avtorite, klu~ni zborovi i tekstot na
apstraktot. Stru~nite trudovi napi{ani na make-
donski jazik na krajot treba da sodr`at rezime na-
pi{ano na angliski jazik vo koe treba da se vklu-
~eni istite podatoci.
Primenite rakopisi Ureduva~kiot odbor gi
ispra}a na recenzirawe. Recenziranite trudovi,
zaedno so eventualnite zabele{ki i mislewa na
Ureduva~kiot odbor, se dostavuvaat do avtorite.
Tie se dol`ni najdocna vo rok od 30 dena da gi
izvr{at neophodnite korekcii i finalnata ver-
zija na rakopisot da ja dostavat do Ureduva~kiot
odbor vo pe~atena forma i zadol`itelno i na PC
formatirana disketa (Word; Times New Roman,
Mac C Times, Macedonian Times i golemina na
bukvi 11).
Avtorite dobivaat 20 besplatni separati od
sekoj trud objaven vo Biltenot. 
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INSTRUCTIONS FOR AUTHORS
Macedonian Pharmaceutical Bulletin is an official pub-
lication of the Macedonian Pharmaceutical Association.
The journal publishes original scientific papers, short com-
munications, reviews and professional papers from all fields
of pharmacyand corresponding scientific fields of interest
for pharmacy (pharmaceutical and medicinal chemistry,
immunology and imunochemistry, molecular biology, phar-
maceutical analyses, drug quality control, pharmaceutical
technology, pharmacoinformatics, biopharmacy, pharma-
cology, applied botany, pharmacognosy, toxicology, clinical
pharmacy, food and nutrition, physical pharmacy, organical
synthesis, social pharmacy, history of pharmacy etc.).
The Macedonian Pharmaceutical Bulletin, also, pub-
lishes and other contributions (recommendations and
announcements, reports of meetings, important events and
dates, book reviews, various rubrics).
Original scientific papers should contain own unpub-
lished results of completed original scientific research.
The number of pages (including tables and figures) should
not exceed 15.
Short communications also should contain completed
but briefly presented results of original scientific research.
The number of pages should not exceed 5 (including one
table and one figure).
Reviews are written at the invitation of the Editorial
Board. They should be surveys of the investigations and
knowledge of several authors in a given research area, the
competency of the authors of the reviews being assured by
their own published results.
Professional papers report on useful practical results
which are not original but help the results of the original
scientific research to be adopted into practical use.
Professional papers might be based on the elaborating of
theoretical data. The number of pages should not exceed
10 (including tables and figures).
Original scientific papers, short communications and
reviews should be written in 
English, while professional papers and all other contri-
butions may be submitted in Macedonian.
Acceptance for publication in the Bulletin obliges the
authors not to publish the same results elsewhere.
Preparation of manuscripts:
Manuscripts should be submitted in triplicate, typed (1
½ spaced) on A4 paper with margins of 3.0 cm on each
side. It is recommended the manuscript be sent on the
Editor-in-Chief address's:





The pages and appendices should be numbered. 
The papers should be written in the shortest possible
way and without unnecessary repetition. 
Obligatorily, only the follow quantities and units must
be used: length (m, cm, mm, μm, nm, Å); weight (kg, g mg,
μg, ng, pg); volume (l, ml, μl); time (s, min, h, d); tempera-
ture (oC, K); radiation (Bq, Ci, dpm, Gy, rad); concentra-
tion (M, mol/l, N, mg/ml, %, %(v/v), %(w/v), ppm).
The names of substances should be in accordance with
the IUPAC recommendations and rules or Chemical
Abstracts practice.
Figures (photographs, diagrams and sketches) and
structural formulae should each be given on a separate
sheet (the place to which they belong in the text should be
indicated). The tables and the figures should be numbered
in Arabic numerals (e.g. Table 1, Fig. 1).
Manuscript should contain: title, abstract, key words,
introduction, experimental, results and discussion, conclu-
sion, acknowledgment (if desired) references and summary.
Papers should be preceded by a title page comprising: the
title, the complete name(s) of the authors, and the author's
affiliations (institution and address). When the authors affil-
iated from various different institutions the origin of the
each author should be indicated with 1,2,3... at the end of
his name. The correspodence author should be indicated
with * and his e-mail address, telephone and fax number to
be supplied in the bottom left part of the title page.
Each paper must begin with an Abstract which should
not exceed more than 250 (original scientific and profes-
sional papers) or 100 (short communications) words. The
abstract should include the aim of the research, methods
and the most important results. A list of 3 to 6 key words
arranged in the order according to their importance should
follow the abstract.
In the introduction only the most important previous
results related to the problem in hand should be briefly
reviewed and the aim and the importance of the research
should be stated.
The experimental section should be written as a sepa-
rate section and should contain a description of the materi-
als used and methods employed in form which makes the
results reproducible, but without detailed description of
already known methods.
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Instructions for authors
Manuscripts which are related to theoretical studies,
instead of experimental, should contain a sub-heading and
the theoretical background where the necessary details for
verifying the results obtained should be stated.
It is often advantageous to combine Results and Discus-
sion in one section. The discussion should contain an analy-
sis of the results and the conclusions that can be drawn.
Conclusion which is in consequence from the presented
results and discussion should be given in the separate section.
The list of references should only include works that
are cited in the text and that have been published or
accepted for publication. References should be numbered
in the order in which they appear in the text and listed in
numerical order in the reference list. 
The surname of one or two authors may be given in the
text, whereas in the case of more than two authors they
should be quoted as, for example Vetter et al. (1).
Papers from scientific journals should be cited as follows:
1. P. Premov and D. Dulanov, Maced. Pharm. Bull. 20,
2-10 (2000).
The names of journals should be abbreviated as in
Chemical Abstracts.
Books should be cited as follows:
2. A. Robert, M. Sporn, Progress in Organic Chemistry,
3rd ed., Butterworths Scientific Publications, London,
1998, pp 125-154.
Books with editor:
3. J. Cook, in The retinoids, P. Cornwell, Ed., Academic
Press, Orlando, 1996, pp 25-29.
Manuscripts written in English should contain a sum-
mary in Macedonian at the end of the paper. The summary
should contain: title, author(s) full-name(s), surname(s),
author's affiliations (institution and address), key words
and abstract. Professional papers written in Macedonian
should contain a summary in English in which the same
data should be included.
Papers received by the Editorial Board are sent to refer-
ees. The suggestions of the referees and Editorial Board
are sent to the author(s) for further action. The corrected
text should be returned to the Editorial Board as soon as
possible but in not more than 30 days in a hard copy form
and obligatorily on the PC formatted disk (Word; font
Times New Roman, Mac C Times, Macedonian Times
and size 11).
Twenty reprints of each paper are supplied free of
charge to the author(s).
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